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ENCOURAGING MATERNAL SACRIFICE: HOW
REGULATIONS GOVERNING THE CONSUMPTION OF
PHARMACEUTICALS DURING PREGNANCY
PRIORITIZE FETAL SAFETY OVER MATERNAL
HEALTH AND AUTONOMY
GREER DONLEY
ABSTRACT

Pregnant women are routinely faced with the stressful decision of whether
to consume needed medications during their pregnancies. Because the risks
associatedwith pharmaceuticaldrug consumption duringpregnancy are largely
unknown, pregnant women both inadvertently consume dangerous medications
and avoid needed drugs. Both outcomes are harmful to pregnant women and
theirfetuses.
This unparalleledlack of drug safety information is a result of ill-conceived,
paternalisticregulations in two areas of the law: regulationsgoverning ethical
research in human subjects and regulations that dictate the required labels on
drugs. The former categorizes pregnant women as "vulnerable" and thus
precludes them from most medical research. The result is that ninety-one percent
of drugs lack any reliable safety informationfor pregnant consumers. The latter
currently requires all drug labels to encourage drug avoidance during
pregnancy, despite ample evidence that avoiding needed medications can harm
pregnant women. On June 30, 2015, new pregnancy labeling regulations took
effect. Though these regulationsmake important improvements, they continue to
treat pregnant women unlike any population, including other unique
subpopulations, such as children. As a result, the new regulations do not fix the
problem of over-warningpregnantwomen about the risks of drug consumption.
This article questions the legitimacy of both regulations and suggests three
reforms for how to improve access to vital safety information: (1) amend the
regulationsgoverning ethical research in human subjects to reclassify pregnant
women as non-vulnerable adults; (2) create incentives to generate safety data in
pregnant women by granting a period of market exclusivity for drug companies
that invest in this research;and (3) make the FDA pregnancy labeling
regulations consistent with the routine FDA practice of requiring the display
of balanced, human data on risk.
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INTRODUCTION

There is an extensive regulatory landscape surrounding the development of
pharmaceutical drugs. These regulations aim to protect both the ultimate
consumers of drugs and the participants of medical research-research that is
required to generate the drug safety evidence necessary to protect consumers.
These regulations treat pregnant women in a paternalistic manner. Medical
research involving human subjects is governed by institutional review boards
("IRBs"). Under the current official IRB regulations, which are governed by
federal regulation,' pregnant women are considered a "vulnerable population"i.e., more susceptible to coercion-and are therefore functionally prevented from
participating in medical research protocols that are available to other adults.2
' J.D., University of Michigan Law School, 2014. I would like to thank Rebecca S. Eisenberg
for her thoughtful feedback in drafting this article and encouragement of my work. I would also
like to thank the editorial staff at the N. Y. U Review of Law & Social Change for their thorough,
insightful, and helpful comments throughout the editing process. An earlier version of this article
was the first place recipient of the Law Students for Reproductive Justice (LSRJ) 2014 Sarah
Weddington Writing Prize for New Student Scholarship in Reproductive Rights. It also won
second place in the 2014 H. Thomas Austern Memorial Writing Competition sponsored by the
Food and Drug Law Institute.
1. Protection of Human Subjects, 45 C.F.R. pt. 46 (2013).

2. Id. § 46.201-09; see also 73 Fed. Reg. 30,831, 30,840-41 (proposed May 29, 2008) (to be
codified at 21 C.F.R. pt. 201) ("Except for the few products developed to treat conditions unique to
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This categorization has greatly chilled medical research on pregnant women,
with the result that hardly any evidence exists regarding a drug's safety in
pregnant women or fetuses. 3 Furthermore, under the U.S. Food and Drug
Administration's ("FDA") current pregnancy labeling regulations, 4 this lack of
information is used to discourage pregnant women from taking medications due
to their unknown risk of fetal harm. 5 This unknown risk to the fetus is not
balanced against the known harms that women and fetuses face when needed
medications are avoided. 6 These labeling regulations are much more
7
conservative than what is required for other subpopulations, such as children.
In tandem, these two sets of regulations have serious consequences for
pregnant women. Women continue to need and consume pharmaceutical drugs
during pregnancy, but must make their medication decisions with insufficient
information as to the relative risks.8 This creates a Catch-22 in which the lack of

&

pregnancy, prescription drugs are not tested in pregnant women prior to their approval. Therefore,
human data concerning a drug's effect(s) on pregnant women and their offspring almost never
come from controlled clinical trials.").
3. For a critical view, see Anne Drapkin Lyerly, Margaret Olivia Little & Ruth Faden, The
Second Wave: Toward Responsible Inclusion of Pregnant Women in Research, I INT'L J. FEMINIST
APPROACHES TO BIOETHIcS 5 (2008) [hereinafter The Second Wave]; Kate Greenwood, The
Mysteries of Pregnancy: The Role of Law in Solving the Problem of Unknown but Knowable
Maternal-FetalMedication Risk, 79 U. CIN. L. REV. 267 (2011); Anne Drapkin Lyerly, Margaret
Olivia Little & Ruth R. Faden, Pregnancy and Clinical Research, HASTINGS CTR. REPORT. Nov.Dec. 2008, at back cover [hereinafter Pregnancy and Clinical Research]; Anne Drapkin Lyerly,
Margaret Olivia Little & Ruth R. Faden, Reframing the Framework: Toward Fair Inclusion of
Pregnant Women as Participants in Research, II AM. J. BIOETHICS 50 (2011) [hereinafter
Reframing the Framework]; Margaret Olivia Little, Anne Drapkin Lyerly & Ruth R. Faden,
Pregnant Women & Medical Research: A Moral Imperative, 2 BIOETHICA FORUM 60, 61-62
(2009) [hereinafter A Moral Imperative]; CTR. FOR BIOLOGICS EVALUATION & RESEARCH, FOOD
DRUG ADMIN., REVIEWER

GUIDANCE EVALUATING THE RISKS OF DRUG EXPOSURE IN HUMAN

at
available
GUIDANCE],
REVIEWER
[hereinafter
(2005)
3
PREGNANCIES,
http://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucml 33359.p
df ("Consequently, when a drug is first marketed there are usually no human data on the effects of
in utero drug exposure. The only data on fetal effects initially available in the product labeling
usually comes from animal reproductive toxicology studies.").

4. 21 C.F.R. § 201.57(c)(9)(i)(A)(l)-(5) (2014).
5. Id.
6. Id.
7. See generally 21 C.F.R. § 201.57 (2014) (imposing regulation requirements for various
subpopulations).
8. 73 Fed. Reg. at 30,841; see also REVIEWER GUIDANCE, supra note 3, at 3 ("Despite the lack
of information on the safety of drug use during pregnancy, most pregnant women likely will be
exposed to drugs. Fetal exposure can occur before a woman knows she is pregnant. Some women
enter pregnancy with medical conditions that require continuing drug therapy. New medical
problems may develop during, or old ones may be exacerbated by, pregnancy."). Some studies
estimate that as many as seventy percent of women from 2006 to 2008 used at least one
prescription drug during their pregnancy. See, e.g., Allen A. Mitchell, Suzanne M. Gilboa, Martha
M. Werler, Katherine E. Kelley, Carol Louik, Sonia Hernindez-Diaz & Nat'l Birth Defects
Prevention Study, Medication Use During Pregnancy, With ParticularFocus On Prescription
Drugs: 1976-2008, 205 AM. J. OBSTETRICS & GYNECOLOGY 51.el, 51.e4 (2011); see also David
W. Kaufman, Judith P. Kelly, Lynn Rosenberg, Theresa E. Anderson & Allen A. Mitchell, Recent
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reliable data forces pregnant women in need of medication to choose between
two potentially risky options: avoid needed medications altogether or consume
potentially risky drugs. On the one hand, avoiding needed medications during
pregnancy can cause negative health consequences for both pregnant women and
their fetuses. 9 On the other, given that both pregnant women and their fetuses
metabolize drugs differently from other adults, drug consumption during
pregnancy can cause adverse reactions in both parties. 10 This dilemma, at best,
can cause significant anxiety for pregnant women choosing whether to consume
medications;" at worst, it can cause blind decision-making, which can lead to
physical harm of the pregnant woman and/or fetus. 12
This article argues that the regulation of pregnant women in medical
research and FDA labeling has created a system in which pregnant women-and,
by consequence, their fetuses-are unprotected from drug risks. Pregnant
women are not more susceptible to coercion than other adults, and should not be
classified as a vulnerable population within the IRB regulations. They should be
given equal opportunity to participate in any research protocol that meets the
standard criteria for ethical adult research as established in 45 C.F.R. § 46.111.
Imposing more stringent regulations on pregnant women is based on
paternalistic notions that value the protection of the fetus over the pregnant
woman's health, autonomy, and well-being. Furthermore, these regulations
ignore the fact that the health of the pregnant woman and fetus are linked. To the
extent that a pregnant woman suffers adverse health effects that result from
insufficient safety information, her fetus may as well.13
The unfortunate consequence is that pregnant women regularly ingest drugs
whose risks are unknown because it is too unpalatable to enroll them in medical
research where they would also be exposed to unknown risks. Unlike the risks
assumed in the research context, the risks pregnant women assume from using
drugs off-label in the clinical setting are not accompanied by the benefit of
generating safety data that would improve public health in the future.
Part I of this article explores how the IRB regulations, which limit and
define ethical research in human subjects, 14 undermine the autonomy of pregnant

Patterns of Medication Use in the Ambulatory Adult Population of the United States, 287 J. AM.
MED. Ass'N 337 (2002) (concluding that nearly fifty percent of women used at least one
prescription drug during their pregnancy and seven percent used five or more). See supra note 3
for various references regarding the lack of drug safety information in pregnancy.
9. See The Second Wave, supra note 3, at 6-7.
10. Id. at 8-9.
I1. Women experience anxiety about using pharmaceuticals during pregnancy, in part due to
an overestimation of the risks of drug consumption in pregnancy. See REVIEWER GUIDANCE, supra
note 3, at 3 ("This exaggerated fear could lead to termination of a wanted pregnancy or to
unnecessary withholding of needed drug therapy during pregnancy.").
12. See infra Part I.B.
13. See The Second Wave, supra note 3; Greenwood, supra note 3, at 268; A Moral
Imperative, supra note 3. For further discussion, see infra Part .B.

14. 45 C.F.R. §§ 46.101-46.505 (2013).
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women by preventing them from consenting to medical research due to their
perceived vulnerability. It explains that pregnant women are not vulnerable to
coercion and that classifying them as such harms the very group the regulations
intend to protect. Part II examines the consequences of the FDA's pregnancy
labeling regulations, which govern drug-consumption warnings for pregnant
women. It first analyzes the current FDA pregnancy labeling regulations,15 and
concludes that the required pregnancy warnings are overly cautious, present
unreliable data derived from animal research, and exclusively focus on fetal risk.
Part II.B then explores the new pregnancy labeling regulations, 16 which were
proposed in 2008 and finalized in December 2014.17 The regulations, which
become effective in June 2015 and must be implemented by 2020,18 make
important improvements; however, they remain overly cautious, focus
predominantly on fetal risk, and increase reliance on animal data. Ultimately,
they will not fix the real problem: the need for an unbiased presentation of
human data.
Part III suggests a three-part solution: (1) remove pregnant women from the
vulnerable population category in the IRB regulations, which will eliminate
unnecessary barriers to their participation in research. This would demonstrate
trust in the ability of pregnant women to make reasonable choices for themselves
and their fetuses. (2) Create financial incentives to generate this data by granting
a three-month period of market exclusivity as is done in the pediatric context.
This will encourage drug companies to invest in this research. And (3) alter the
pregnancy labeling requirements to mirror other populations so that reliable
human data is presented neutrally and pregnant women can make informed
choices.

I.
THE HARMFUL OVERREGULATION OF PREGNANT WOMEN IN MEDICAL
RESEARCH

Before a pharmaceutical can enter the market, drug companies must
overcome many scientific and regulatory barriers. Drug companies must first
perform years of pre-clinical research in animals to justify research in humans. 9

15. 21 C.F.R. § 201.57(c)(9)(i)(A)(l)-(5) (2014).
16. 73 Fed. Reg. 30,831 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt. 201).
17. 79 Fed. Reg. 72,064 (proposed Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201).

18. Id. at 72,064, 72,095-72,096.
19. OFFICE FOR HUMAN RESEARCH PROTS., U.S. DEP'T OF HEALTH & HUMAN SERVS., INST.

REVIEW BD. GUIDEBOOK, ch. 6 (2d ed. 1993), available at http://www.hhs.gov/ohrp/archive/irb/
irb chapter6.htm [hereinafter GUIDEBOOK] (describing the relationship between animal studies,
Investigational New Drug Applications, and phase one clinical trials in the "Overview" section).
For information on the average length of time pre-clinical studies take, see Judy Stone, Molecules
to
Medicine:
Clinical
Trials
for
Beginners,
Sc.
AM.
(Oct.
6,
2011),
http://blogs.scientificamerican.com/guest-blog/2011/10/06/molecules-to-medicine-clinical-trialsfor-beginners/.
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Once clinical research in human participants is warranted, researchers must
submit their proposed human research protocols to IRBs, which review the
research to determine whether or not the research is ethical. 20 IRB approval is
time-consuming and expensive. In one study, the process of obtaining IRB
approval for a multi-site research protocol cost researchers more than $56,000
(seventeen percent of the total research grant) 21 and took 4,680 hours over 798
days. 22 Adding to this cost is the fact that each drug must pass through three
phases of clinical trials, with IRB approval required at each phase. 23 In total, it
can take a drug company a decade or more to generate the necessary human data
to submit a New Drug Application to the FDA for approval. 24
Federal law requires that IRBs approve all medical research in human
subjects before the research begins. 25 IRBs are generally housed within a
research institution and review medical research proposals according to federal
guidelines that define ethical research. 26 45 C.F.R. § 46.111(a) ("Subpart A")
outlines seven criteria necessary for IRB approval of research in human subjects,
including both vulnerable and non-vulnerable populations. This section requires
that: (1) risks to subjects are minimized; (2) risks to subjects are reasonable in
relation to anticipated benefits; (3) selection of subjects is equitable; (4)
informed consent is sought from each prospective subject (defined in greater
detail in 45 C.F.R. § 46.116); (5) informed consent is appropriately documented;
(6) when appropriate, the collected data is monitored to ensure the safety of
subjects; and (7) the privacy of subjects is protected.2 7 If the IRB believes that a
research protocol fails to meet any of these seven requirements, it can reject the
proposal outright, which would terminate the research project immediately, or
accept the protocol only after the research team makes the revisions it requests. 28
In addition to the criteria listed in Subpart A, research in pregnant women
must also meet the stricter regulations found in 45 C.F.R. § 46.204 ("Subpart

&

20. National Research Act, Pub. L. No. 93-348, 88 Stat. 342 (1974); 45 C.F.R. § 46.103
(2014).
21. Keith Humphreys, Jodie Trafton & Todd H. Wagner, The Cost of Institutional Review
Board Proceduresin Multicenter ObservationalResearch, 139 ANNALS OF INTERNAL MED. 77, 77
(2003).
22. Lee A. Green, Julie C. Lowery, Christine P. Kowalski & Leon Wyszewianski, Impact of
Institutional Review Board Practice Variation on Observational Health Services Research, 41
HEALTH SERVS. RESEARCH 214, 219-20 (2006).
23. The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. FOOD
DRUG
ADMIN.,
http://www.fda.gov/drugs/resourcesforyou/consumers/ucml43534.htm
(last
updated Nov. 16, 2014).
24. See Stone, supra note 19.
25. National Research Act; 45 C.F.R. § 46.103.
26. See ERIN D. WILLIAMS, CONG. RESEARCH SERV., FEDERAL PROTECTION FOR HUMAN
RESEARCH SUBJECTS: AN ANALYSIS OF THE COMMON RULE AND ITS INTERACTIONS WITH FDA
REGULATIONS AND THE HIPAA PRIVACY RULE 2 (2005), available at http://www.fas.org/sgp/crs/
misc/RL32909.pdf.
27. 45 C.F.R. § 46.111(a) (2013).
28. Id.
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B"), entitled "Additional Protections for Pregnant Women, Human Fetuses and
Neonates Involved in Research." 29 Part L.A of this article examines the
regulatory hurdles of Subpart B, which a researcher must overcome to conduct
research involving pregnant women or fetuses. Part I.B of this article discusses
the practical implications of these regulations: pregnant women are largely
excluded from all medical research and, as a result, there is little drug-safety
information available for this group.3 0 Because pregnant women continue to
consume drugs despite the lack of safety information, the result is that these
regulations, although ostensibly protective, generate unnecessary risk and harm
to women and fetuses.3 1 Part I.C of this article explores whether or not this harm
is justified, and concludes that it is not. The justification rests on the
categorization of pregnant women as "vulnerable to coercion or undue
influence," 32 yet there is no reason to believe pregnancy clouds a woman's
decision-making capacity or makes her unable to resist pressure. Because the
justification for these regulations is ill conceived, the harm is unwarranted.
Feminist bioethicists have previously criticized the consequences of
excluding pregnant women from medical research33 ; however, despite these
arguments, there have not been legislative or regulatory efforts to alter this
practice. Part I aims to look at the problem through a different disciplinary
perspective by bringing this issue to light in the legal literature.
A.

The Regulatory Criteriafor Ethical Research in Pregnant Women

The criteria outlined in Subpart A establish the baseline requirements for
ethical research in human subjects. Research in pregnant women, however, is
also subject to the more extensive regulations outlined in Subpart B. 34 These
regulations require that the proposed research have the potential to benefit the
pregnant woman directly. 35 If the research does not have the prospect of direct

benefit, a pregnant woman is prohibited from enrolling in the study if it poses a

29. 45 C.F.R. § 46.204 (2014).
30. See supra discussion accompanying note 3; W. Y. Lo & J. M. Friedman, Teratogenicity
of Recently Introduced Medications in Human Pregnancy, OBSTETRICS & GYNECOLOGY, 465, 468
(2002) (finding that 91.2% of drug treatments approved in the US between 1980 and 2000 did not
have human safety data on use during pregnancy).
31. See infra discussion in Part lB.
32. 45 C.F.R. § 46.111(b). The term vulnerable is not defined in the regulations. However, it
is clear that the regulators assumed some sort of cognitive vulnerability by, at one point, referring
to it as a vulnerability to coercion or undue influence: "When some or all of the subjects are likely
to be vulnerable to coercion or undue influence, such as children, prisoners, pregnant women,
mentally disabled persons, or economically or educationally disadvantaged persons, additional
safeguards have been included in the study to protect the rights and welfare of these subjects." Id.
33. See supra discussion accompanying note 3.
34. 45 C.F.R. § 46.201-207 (2014). Subpart C (45 C.F.R. § 46.301-306) relates to prisoners
and Subpart D (45 C.F.R. § 46.401-409) relates to children.

35. § 46.204(b).

Imaged with Permission of N.Y.U. Review of Law & Social Change

Vol. 39:45

N.Y. U. REVIEW OF LAW & SOCIAL CHANGE

52

"greater than minimal risk" to her fetus.36 The purpose of the research must be
the development of important biomedical knowledge that cannot be obtained by
any other means. 37 Overall, Subpart B contains ten provisions; however, two of
them-Sections (a) and (b)-are primarily responsible for the lack of research in
pregnant women.38
First, when scientifically appropriate, the IRB reviewing a research proposal
must have access to preclinical trials in pregnant animals to assess the risk to
fetuses and pregnant women.39 The IRB must also have access to data on clinical
trials in non-pregnant women. 40 This poses two obstacles to conducting trials in
pregnant women. First, drug companies must invest in costly studies of pregnant
animals. 41 Second, pregnant women can be enrolled only after clinical trials have
already been conducted in non-pregnant women. This two-trial requirement is
also expensive. 42 Because there is no regulatory requirement to generate
information on drug safety in pregnancy, 43 and drug companies are not forced to
compete according to this measurement,44 there is no financial incentive for drug
companies to spend the money investing in this research. 45

36. § 46.204(d).
37. Id.; see also Christine Grady & Colleen Denny, Research Involving Women, in THE
OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 409

(Ezekiel J. Emanuel, Christine Grady,

Robert A. Crouch, Reidar K. Lie, Franklin G. Miller & David Wendler eds., 2008).

38. § 46.204(a)-(b).
39. § 46.204(a).
40. Id
41. While drug companies must already invest in animal studies to be granted an
Investigational New Drug Application from the FDA so that they can begin their research in
humans, there is no requirement to do pre-clinical studies on pregnant animals for every drug. 21
C.F.R. § 312.23(a)(8) (2014); GUIDEBOOK, supra note 19. The cost of such additional studies is
high, especially given the difficulty in obtaining pregnant animals. See EUROPEAN FED'N OF
PHARM.

INDUS.

& Ass'NS,

MAKING

SENSE OF ANIMAL

RESEARCH

7 (2008),

available at

http://www.animalresearchforlife.eu/Makingsenseofanimal_research.
42. In 2007, pharmaceutical and biotechnology companies spent nearly sixty billion dollars
on drug research. Clinical Trials Facts and Figures, CTR. FOR INFO. & STUDY ON CLINICAL
RESEARCH
PARTICIPATION,
https://www.ciscrp.org/wp-content/uploads/2014/03/
ciscrp dataarchivefacts and figuresforhealth professionals.pdf (last visited Dec. 8, 2013).
Clinical trials now constitute sixty percent of drug development costs. Furthermore, to the extent
the clinical trials on pregnant women or research on pregnant animals delayed bringing a drug to
market, it would cost a drug company $8 million per day.
43. It is only required when seeking to produce a drug intended for use in that population. 21
C.F.R. § 312.23(a)(8)(ii)(a) (2014) ("Depending on the nature of the drug and the phase of the
investigation, the description is to include the results of acute, subacute, and chronic toxicity tests;
tests of the drug's effects on reproduction and the developing fetus."). See generally 21 C.F.R. §

312.23(a)(8).
44. Given that drug companies as a whole do not produce this information, and at this point,
pregnant women have not demanded it, there has been no market pressure to invest in these studies
so as to gain a competitive market edge.
45. A Moral Imperative, supra note 3, at 63 ("All will agree that regulations should restrict
when and how research can be conducted on pregnant women. But without any legislative or
regulatory pressure to include pregnant women in some fashion, a powerful, systemic incentive
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Second, Subpart B requires that any risk posed to the fetus must be
outweighed by the prospect of benefit to either the fetus or the pregnant woman;
otherwise, the risk must be minimal (defined as not greater than the risks
encountered in everyday activities or routine procedures) 46 and necessary to
obtain scientific knowledge. 47 Practically speaking, any risk that a drug poses to
a fetus will be interpreted as beyond minimal risk-a fetus encounters very few
risks from everyday activities or routine procedures, and any unknown harmful
effects of a drug could produce serious complications in a developing fetus.48
Thus, the issue debated by IRBs is whether the potential for maternal benefit
might outweigh the potential for fetal risk. This is extremely difficult to quantify
and the result is that IRBs tend to overestimate fetal risk and underestimate
maternal benefit. 49
Subpart B regulations are only concerned with fetal, not maternal risk 5o-if
an experimental therapy poses only risks to the pregnant woman and not the
fetus, then the regulations do not require that the risk be outweighed by potential

-

structure is established. It is easier for researchers to side-step the regulatory burden that pregnant
women currently represent by excluding them wholesale from all research, including research that
imposes no risk, or risk that is clearly reasonable in its context. Without changing the burdens of
justification, all the incentives to the research community line up in favor of simply ignoring
pregnant women.").
46. Minimal risk is defined as follows: "A risk is minimal where the probability and
magnitude of harm or discomfort anticipated in the proposed research are not greater, in and of
themselves, than those ordinarily encountered in daily life or during the performance of routine
physical or psychological examinations or tests. For example, the risk of drawing a small amount
of blood from a healthy individual for research purposes is no greater than the risk of doing so as
part of routine physical examination." GUIDEBOOK, supra note 19, at ch. 6. For a list of research
methods presumed to pose minimal risk, see Office for Human Research Protections (OHRP)
Categories of Research, U.S. DEP'T HEALTH & HUMAN SERVS., http://www.hhs.gov/ohrp/policy/
expedited98.html (last visited Dec. 8, 2013).

47. 45 C.F.R. § 46.204(b) (2013).
48. Despite a very low probability that a drug could cause birth defects, the nature of birth
defects, and their possible preventability, means that IRBs and government agencies take them
very seriously. See REVIEWER GUIDANCE, supra note 3, at 2 ("About 4 percent (1/28) of babies are
born each year with a major birth defect or congenital malformation .... Chemically induced birth
defects, including those associated with drug exposure, probably account for less than 1 percent of
all birth defects . . . . Of the thousands of drugs available, only about 20 drugs or groups of drugs
... are recognized as having an increased risk of developmental abnormalities when used clinically
in humans. However, since few drugs have been systematically studied to identify their full range
of possible teratogenic risks, we cannot assume that current knowledge is complete. The
identification of a drug's teratogenic potential is important because drug-induced adverse fetal
effects are potentially preventable."); see also GUIDEBOOK, supra note 19.
49. Toby Schonfeld, The Perils of Protection: Vulnerability and Women in Clinical
Research, 34 THEORETICAL MEDICINE & BIOETHICS 189, 196 (2013). For an examination of the
overestimation of risk for medical interventions in the clinical setting for pregnant women, see
Anne Drapkin Lyerly, Lisa M. Mitchell, Elizabeth Mitchell Armstrong, Rebbeca Kukla, Miriam
Kuppermann & Margaret Olivia Little, Risk and the Pregnant Body, 39 HASTINGS CTR. REPORT.

34, 34-35 (2009).
50. Nowhere in 45 C.F.R. § 46.204(b) is maternal risk mentioned-maternal benefit must be
balanced against fetal risk. Compare this to 45 C.F.R. § 46.111 (a)(2), where the benefit to the adult
must be balanced against the risk to the adult.
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for direct benefit. Instead, the general standard for risk, found in Subpart A
applies to pregnant women as it applies generally to all adults. It requires that
risk be "reasonable in relation to anticipated benefits [to her]."5 1 This results in a
dichotomy: risks to the fetus are treated as grave while risks to the pregnant
woman are treated as due course. This is despite a similar lack of knowledge
about how a given drug could affect the pregnant woman, who could also have
an unknown adverse drug response as a consequence of pregnancy. 52
There are other substantive differences between the Subpart B regulations,
which govern research in pregnant women, and the Subpart A regulations, which
govern research in all adults. Any risk posed by research in pregnant women
must be "the least possible" to achieve the objectives of that research.53 By
contrast, the risks of research in other adults must simply be minimized. 54 This
stricter language further contributes to IRBs' reluctance to approve research in
pregnant women. The regulations also require a pregnant woman's informed
consent, as that term is defined in Subpart A.55 This is the same informedconsent requirement that applies to other adults. 56 However, there are two
additional components that alter the informed consent process. First, if the
research participation is solely to benefit the health of the fetus, the pregnant
woman's partner must also consent to the woman's research participation. 57 This
is unless the partner "is unable to consent because of unavailability,
incompetence, or temporary incapacity or the pregnancy resulted from rape or
incest."58 Second, whoever consents to the research must be informed of any
foreseeable impact on the fetus.59 Pregnant minors must provide consent
according to the regulations for children, as well as obtain parental permission. 60
The regulations also include three prohibitions related to abortion: researchers
cannot provide inducements for abortion, advise on whether, how, or when to
terminate a pregnancy, or determine fetal viability.6 1

51. 45 C.F.R. § 46.111(a)(2) (2013).
52. The Second Wave, supra note 3, at 7; A Moral Imperative, supra note 3, at 61.

45 C.F.R. § 46.204(c) (2013) (emphasis added).
§46.111(a)(1).
§ 46.204(d).
§ 46.111 (a)(4).
§ 46.204(e).
58. Id. This article's description of § 46.204(e) deviates from the exact language of the
53.
54.
55.
56.
57.

regulation to avoid hetero-normativity. The exact text of the regulation uses the male pronoun to
refer to a pregnant woman's partner and discusses the necessity of obtaining the "father's consent."

59. § 46.204(f).
60. § 4 6.204(g).
61. § 46.204(h)-(j).
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Regulations governing research in pregnant women are significantly more
burdensome than those that regulate research in other adults. 62 They are costly
and create regulatory hurdles for researchers desiring to conduct research in this
population. While Subpart B does not prohibit research in pregnant women, and
seems reasonable on its face, it has widespread consequences.63 Part I.B of this
article explores these practical implications and the harmful impact they have
had on pregnant women and fetuses.
B.

Consequences of the IRB Regulations

The burden these regulations impose is reflected in the infrequency with
which trials in pregnant women occur. The reality is that "many researchers and
IRBs continue to regard pregnancy as a near-automatic cause for exclusion."64
Thus, even if a drug company is willing to pursue the additional cost associated
with research in pregnant women (by first testing drugs in pregnant animals and
repeating trials after they have been conducted in non-pregnant women), IRBs
will make it very difficult to conduct this research. As a result, only 0.7 percent
of drugs have been approved for use in pregnant women,65 and 91.2 percent of
drugs lack any human safety data on consumption during pregnancy."
This lack of data is particularly concerning because pregnant women and
their fetuses process and metabolize drugs differently from other adults. 67 This is
in large part due to the physical changes that accompany pregnancy as:
Pregnancy alters the impact of sex differences on absorption,
distribution, metabolism, and excretion of drugs-often times in
ways that are both dramatic and difficult to predict. Pregnancyrelated changes in the gastrointestinal tract, the cardiovascular
system, the kidneys, and other organs may profoundly alter the
ways that drugs are processed by the body (pharmacokinetics) or
the ways that drugs act on the body (pharmacodynamics). 68
Case studies have documented the impact of this phenomenon. For instance,
in one study, a pregnant woman undergoing chemotherapy metabolized and
excreted the drug "so quickly and thoroughly that the drug never approached a

62. Compare 45 C.F.R. § 46.111(a) (denoting the criteria for IRB approval of research in
general), with § 46.204 (denoting the more stringent requirements for research involving pregnant
women or fetuses).
63. See supra note 3 for a discussion about the lack of drug safety data in pregnant women.
64. The Second Wave, supra note 3, at 6.
65. See J.M. Friedman, Report of the Teratology Society Public Affairs Committee
Symposium on FDA ClassificationofDrugs, 48 TERATOLOGY 5 (1993).
66. Lo & Friedman, supra note 30, at 468.
67. See The Second Wave, supra note 3, at 8-9; A Moral Imperative, supra note 3, at 61;
Lucy S. Hodge & Timothy S. Tracy, Alterations in Drug Disposition During Pregnancy:
Implicationsfor Drug Therapy, 3 INFORMAL HEALTHCARE 557 (2007).
68. The Second Wave, supra note 3, at 8.
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therapeutic range, despite the fact that she and the fetus were exposed to its
toxicities." 69 A similar effect has been demonstrated with drugs treating diabetes
in pregnancy-the dose provided created side effects without providing
therapeutic benefits. 70 Because pregnancy can dramatically change a woman's
drug response, treatments may need to be altered. 71 The lack of drug safety
information related to pregnancy makes it difficult to determine the appropriate
dosage.
Fetuses also suffer from this lack of information. In the 1950s and 1960s,
for example, pregnant women were routinely prescribed thalidomide. Though
the FDA never approved the drug for use in the United States, it was legally
available for use as a sedative in other countries. 72 Doctors quickly began to
prescribe thalidomide to pregnant women off-label73 for morning sickness
despite a lack of safety information. 74 As a result, "more than 10,000 children in
46 countries were born with malformations or missing limbs." 75 The thalidomide
case study is distinct in that the FDA never approved the drug in the United
States. This example nevertheless demonstrates the possible outcomes associated
with off-label drug use in pregnancy, which occurs routinely in the United States
and is exacerbated by a lack of safety information for pregnant women.
A more recent example is that of antidepressants, which physicians
prescribe during pregnancy for good reason, though without adequate
information. We are only now learning of the potential effects of these drugs on
the fetus, such as correlations with autism, newborn behavioral syndrome,
persistent pulmonary hypertension, and heart conduction problems. 76 Another
noteworthy example is that of assisted reproductive technologies. In a recent
compilation of studies, the risk of birth defects was shown to be 1.36 times
greater in children conceived through assisted reproductive technologies than in
spontaneously conceived children. 77

69. Id at 8-9.
70. Anne Drapkin Lyerly, Margaret Olivia Little & Ruth R. Faden, The National Children's
Study: A Golden Opportunity to Advance the Health of Pregnant Women, 99 AM. J. PUB. HEALTH

1742, 1742 (2009).
&

71. See The Second Wave, supra note 3; A Moral Imperative, supra note 3, at 61; Hodge
Tracy, supra note 67; Lyerly, Little & Faden, supra note 70, at 1742-43.
72. Bara Fintel, Athena T. Samaras & Edison Carias, The Thalidomide Tragedy: Lessons For
Drug Safety And Regulation, HELIX MAGAZINE (July 28, 2009), https://helix.northwestern.edu/
article/thalidomide-tragedy-lessons-drug-safety-and-regulation.
73. Id.
74. Rachel Hajar, Animal Testing and Medicine, 12 HEART VIEwS 42, 42 (2011).

75. Id.

&

76. See Adam Urato, Commentary: More Bad News on Antidepressants and Pregnancy,
COMMON HEALTH (June 12, 2012, 7:43 AM), http://commonhealth.wbur.org/2012/06/
antidepressants-pregnancy.
77. Yan Jia, Li-hong Geng & Ying Zhong, Birth Defects in Assisted Reproductive
Technology and Spontaneously Conceived Children: A Meta-Analysis, 24 J. REPRODUCTION
CONTRACEPTION 237,240 (2013).

Imaged with Permission of N.Y.U. Review of Law & Social Change

2015

ENCOURAGING MA TERNAL SACRIFICE

57

However, the solution does not involve a strict avoidance of medications.
Forgoing treatment out of concern for fetal harm can also result in disastrous
consequences. For instance, the reticence to use CT scans during pregnancy has
led to a delayed diagnosis of appendicitis which can lead to the rupture of the
pregnant woman's appendix and miscarriage. 78 In a nationwide study during the
2009 outbreak of the HINL virus, "women who did not begin antiviral treatment
until more than four days after symptom onset were fifty-four times more likely
79
to die than women who were treated within two days of symptom onset."
Pregnant women who suffer from depression may also face serious
complications when they fail to take needed medications. These complications
include "premature birth, low birth weight, fetal growth restriction, and postnatal
complications. [Depression] also is associated with decreased social support,
poor weight gain, and alcohol and drug use, all of which adversely affect
outcomes for women and infants alike." 80 Without information regarding drug
safety, physicians cannot reliably inform pregnant women about whether it is
safer to avoid or consume certain medications. This creates a treacherous
dilemma for pregnant women: either avoid needed medications that might
improve their own and/or their fetus's health, or use medication off-label without
fully understanding its health effects.
In practice, our society allows pregnant women to consent to the risks of
off-label drug use on behalf of themselves and their fetuses every day. In light of
this, it seems the FDA should trust women to make similar risk calculations
when they consider whether to participate in medical research. Given the sheer
number of women consuming pharmaceuticals in the clinical setting, the risks
associated with clinical off-label drug use are broader and more widespread than
those potentially involved with small number of pregnant women participating in
research.8 ' Unlike the risks assumed by pregnant women in the research context,
clinical off-label drug use in pregnancy lacks the added benefit of generating
data that would eventually reduce overall risks by determining which drugs are
safe for consumption in pregnancy, and which drugs pose risks. 82
The only way to remove these risks in the medical context is to generate
data: "a pregnant woman is not just a woman with a bigger belly . . . . If we are
to treat pregnant women's illnesses effectively-something crucial to the health
of both pregnant women and that of the children they may bear-we must study
medications in pregnant women." Since seventy percent of pregnant women

78. See Lyerly, Mitchell, Armstrong, Harris, Kukla, Kuppermann & Little, supra note 49.
79. Greenwood, supra note 3, at 269.
80. The Second Wave, supra note 3, at 11.
81. Instead of exposing small groups of pregnant women to these risks for small periods of
time through clinical studies, we expose all women to these risks without any end in sight.
82. Clinical trials produce reliable evidence upon which to base clinical decisions. Pregnant
women taking these medications on their own produce no evidence for future benefit.
83. The Second Wave, supra note 3, at 9.
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use prescription drugs every year,8 more robust data could greatly improve
maternal and fetal outcomes. Given these negative consequences, the remaining
question is whether requiring stricter standards for research in pregnant women
is justified. The following Part explores this question in more detail.
C. The CategorizationofPregnant Women as Vulnerable is Unjustified
The regulations governing IRB approval of research classify pregnant
women as a group "likely to be vulnerable to coercion or undue influence."85
This is a designation that pregnant women share with four other groups:
children, prisoners, mentally disabled persons, and economically or
educationally disadvantaged persons. 86 Additional safeguards "to protect the
rights and welfare of these subjects" are required before the IRB can approve a
study involving any of these groups. 87 Only three of the five populations,
however, were considered vulnerable enough to warrant additional, defined
regulations: prisoners,88 children,8 9 and a group referred to as "pregnant women,
human fetuses, and neonates." 90 Before research can occur in these three
populations, an IRB must approve the research protocol according to a higher
standard than the baseline protections established in 45 C.F.R. § 46.111.
Research involving pregnant women must meet the additional requirements of
Subpart B. 91 By contrast, research involving the mentally disabled or the
economically or educationally disadvantaged is not subject to stricter regulations
apart from the safeguards required in § 46.111(b). 92
Children, prisoners, and pregnant women are considered vulnerable because
it is assumed that these groups are particularly susceptible to coercion. 93 Under

84. See Mitchell, Gilboa, Werler, Kelley, Louik, Hemndez-Diaz & Nat'l Birth Defects
Prevention Study, supra note 8.

85.
86.
87.
88.
89.
90.
91.
92.

45 C.F.R. § 46.111(b) (2014).
Id.
Id.
§ 46.301-06.
§ 46.401-07.
§ 46.201-09.
Id.
§ 46.111(b).

93. See Karen J. Schwenzer, Protecting Vulnerable Subjects in Clinical Research: Children,
Pregnant Women, Prisoners, and Employees, 53 RESPIRATORY CARE 1342, 1343 (2008); MARY C.
RUOF,

VULNERABILITY,

VULNERABLE

POPULATIONS,

AND

POLICY

2

(2001),

available at

https://bioethics.georgetown.edu/publications/scopenotes/sn44.pdf ("In clinical research, the term
vulnerable generally is applied to individuals who are unable to give informed consent or who are
susceptible to coercion."); 45 C.F.R. § 46.111(b) ("When some or all of the subjects are likely to
be vulnerable to coercion or undue influence, such as children, prisoners, pregnant women,
mentally disabled persons, or economically or educationally disadvantaged persons, additional
safeguards have been included in the study to protect the rights and welfare of these subjects.").
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this theory, these groups may be unable to resist the incentives or pressure to
94
participate in research, and must be excluded from it for their own protection.
Pregnant women should not be designated as a vulnerable group. Children
and prisoners are truly susceptible to coercion, and these groups do need
additional protections.95 Given the inherent power imbalance between state and
prisoner, and parent and child, it may not be possible for a child or a prisoner to
consent freely to participation in medical research. 96 Parents and prison officials
have the power to punish and reward. This power can pressure the weaker party
to participate in research even if the dominant party never uses her power: "The
vulnerability creating feature here is the extent to which consent or permission to
participate in a study reflects the desires and values of the surrogate decision
maker rather than of the potential participant herself."97 Pregnant women, on the
other hand, are not subject to this sort of coercive pressure.
Other laws that recognize the vulnerability of children and prisonersspecifically, their inability to give free and informed consent-do not extend the
same status to pregnant women.98 For instance, rape laws, where consent is
fundamental to the legality of conduct, generally treat prisoners and children as
incapable of consenting to sexual activity.9 9 Thus, it is a felony for an adult to

94. See GUIDEBOOK, supra note 19.
95. Schonfeld, supra note 49, at 196 ("Juridic vulnerability obtains in situations in which
others have legal authority over the decisional processes of someone. Common examples of these
social situations are parents over children, wardens over prisoners, and military commanders over

enlisted soldiers.").
96. Id.
97. Id.

&

98. See GUIDEBOOK, supra note 19 ("The circumstances common in prisons create
environments in which the offer to participate in research is necessarily coercive or creates a undue
influence in favor of participation. To the extent that living conditions in prison are bad and the
provision of health care is minimal or even nonexistent, the lack of control allowed prisoners and
the desire to obtain the advantages offered to those who agree to participate may preclude their
ability to weigh fairly the risks and benefits involved in participation."); Michelle Roth-Cline
Robert M. Nelson, Parental Permission and Child Assent in Research on Children, 86 YALE J.
BIOLOGY & MED. 291, 291-92 ("For research involving children, both of these safeguards are
modified given the vulnerability of children to undue influence or coercion. There are limits set to
the risks that a child may be exposed to in research that does not offer a prospect of direct benefit
and limits set to the justification of risks that a child may be exposed to in research that offers a
prospect of direct benefit. As discussed below, these additional requirements for research involving
children arise from the difficulty in applying a model of self-determination to parental permission
and child assent.").
99. See NAT'L INST. OF CORR. & THE PROJECT ON ADDRESSING PRISON RAPE AT WASHINGTON
COLLEGE OF LAW, FIFTY STATE SURVEY OF STATE CRIMINAL LAWS ADDRESSING THE SEXUAL
EXPLOITATION OF MINORS (2006) [hereinafter LAWS ADDRESSING THE SEXUAL EXPLOITATION OF

MINORS],

available at http://static.nicic.gov/Library/021769.pdf;

see also THE PROJECT ON

ADDRESSING PRISON RAPE AT WASHINGTON COLLEGE OF LAW, FIFTY-STATE SURVEY OF CRIMINAL
LAWS PROHIBITING SEXUAL ABUSE OF INDIVIDUALS IN CUSTODY (2011) [hereinafter LAWS
PROHIBITING SEXUAL ABUSE].
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have sex with a child or a prison official to have sex with a prisoner.'" Because
the sexual activity cannot be separated from the coercive power dynamic that
exists between adults and children or guards and prisoners, this is a strict liability
crime regardless of any proclaimed "consent."' 01 The policy justification is
nearly identical in medical research-consent to medical research participation
that could be based on the pressure to appease an authority figure should not be
validated. Given the extensive policy justifications for protecting these two
classes of people against coercive influences, it is legitimate to limit their
research participation to studies, which IRBs have determined to be in their best
interests.
Pregnant women, on the other hand, are fully autonomous adults, wholly
capable of giving informed consent. In fact, due to a history of discrimination in
certain contexts like employment, anti-discrimination statutes were enacted to
ensure that women were not inappropriately deemed incapable during their
pregnancies.1 02 Despite the physical impairments that can accompany some
pregnancies, pregnant women do not face any diminished mental or intellectual
capacity. Unlike prisoners and children, pregnant women are legally capable of
consenting to sexual activity. Although historical notions of a pregnant woman's
frailty exist, 0 3 these notions were discredited decades ago. Regarding their
ability to consent, pregnant women are not prevented from entering into
contracts, creating trusts, wills, or advanced directives, or consenting to other
kinds of risks, like military participation or medical interventions1"0 In fact, the
regulations provide little justification for categorizing pregnant women as
vulnerable. 0 5

100. LAWS ADDRESSING THE SEXUAL EXPLOITATION OF MINORS, supra note 99; LAWS
PROHIBITING SEXUAL ABUSE, supra note 99; Patricia J. Falk, Rape by Fraud and Rape by

Coercion, 64 BROOK. L. REv. 39, 101-07 (1998).
101. See Michelle Oberman, Turning Girls Into Women: Reevaluating Modern Statutory
Rape Law, 85 Nw. J. CRIM. L. & CRIMINOLOGY 15 (1994).
102. Pregnancy Discrimination Act, Pub. L. No. 95-555, 92 Stat. 2076 (1978).
103. See generally CLARE HANSON,

A CULTURAL HISTORY OF PREGNANCY: PREGNANCY,

MEDICINE AND CULTURE, 1750-2000, 23-36, 51-71 (2004) (providing a cultural history of
pregnancy between 1750 and 2000).
104. The one important exception to this general rule is in the context of medical decisions
thought by some to not be in the best interest of the fetus. For instance, cases exist in which
physicians override the pregnant woman's wishes and perform a caesarian section. Lisa Collier
Cool, Could You Be Forced To Have A C-Section?, NAT'L ADVOCATES FOR PREGNANT WOMEN
(2005), http://www.advocatesforpregnantwomen.org/articles/forced c-section.htm.
105. Grady & Denny, supra note 37, at 408 ("This label ['vulnerable'], however, does seem
to confuse what entity is vulnerable and at risk. There does seem to be a widely held intuition
among both researchers and the general public that pregnant women require greater protection than
do non-pregnant human beings, but support for that intuition is often unclear, particularly in the
research setting. Most regulation and guidelines offer no explanations for these special protective
measures, and those that do usually refer to the risk of fetal rather than maternal harm during
research participation.").
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More likely, the classification of pregnant women as a vulnerable
population is a pretext for the state's protection of the fetus. 0 6 There is historical
evidence to suspect that Subpart B was really an attempt to express concern for
the unborn: "The vocal pro-life community, galvanized in the wake of the U.S.
Supreme Court's 1973 Roe v. Wade decision, expressed concern for the unborn
fetuses by pushing for stringent limits on women's research participation." 0 7 Dr.
Charles McCarthy has argued that the debate over abortion rights in the wake of
Roe is one of three events that profoundly altered the public's view on medical
research.108 Additional evidence for this contention can be found in the text of
Subpart B, where three of the ten conditions of IRB approval of research in
pregnant women involve limitations on abortion. 09 This is an odd context in
which to insert restrictions on abortion funding; unlike women seeking
abortions, there is no reason to think pregnant research subjects are attempting to
end their pregnancies. Indeed, participating in medical research may indicate a
pregnant woman's desire to improve health outcomes both for herself and for her
fetus. Nevertheless, it is impossible to divorce the issue of medical research on
pregnant women from the context of the ongoing abortion debate.
The strongest justification for the restrictions in Subpart B is based not on
the need to protect the pregnant woman from coercion, but on the inability of the
fetus to give informed consent. Because the fetus cannot consent to the
research-including any side effects that might develop after the fetus is bornthe government undertakes an obligation to protect the fetus from medical
research in a similar way to how it protects children. However, this overlooks
three vital differences between fetuses and children: (1) the fetus's health is
directly linked to the pregnant woman's health while in utero. Thus, any medical
benefit to the pregnant woman is likely to improve fetal health outcomes. (2)
Once the child and woman are separate beings, increasing regulatory protections
for children in research comes at no cost to the mother. Regulatory protections of
the fetus, however, do create costs for the pregnant woman. She may lose the
potential to benefit from medical research, both as a participant and as a pregnant

106. Id.; Schonfeld, supra note 49; GUIDEBOOK, supra note 19 ("The fetus has a unique and
inextricable relationship to the mother. It cannot consent to be a research subject. These
circumstances have aroused lengthy public debate on the ethics of fetal research, and led to special
federal regulations that guide IRB deliberations about fetal research [45 C.F.R. 46 Subpart 13]. The
fetus may also be an indirect subject of research when women who may be pregnant participate.
Research involving pregnant women is also regulated by 45 C.F.R. 46 Subpart B.").
107. Grady & Denny, supra note 37 (citing Roe v. Wade, 410 U.S. 113 (1973)); see also
Charles R. McCarthy, Historical Background of Clinical Trials Involving Women and Minorities,
69 ACAD. MED. 695, 696 (1994) ("The highly emotional abortion debate, including its
connotations, had a chilling effect on research involving women of childbearing potential and
human fetuses.").
108. McCarthy, supra note 107, at 696. In addition to Roe, Dr. McCarthy also cites the
revelation of the Tuskegee syphilis experiment and the irrational exuberance surrounding President
Nixon's "war on cancer" as events that "tended to deter participation in clinical trials by a wide
spectrum of persons who were potential research subjects." Id

109. 45 C.F.R. § 46.204(h)-(j) (2013).
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woman trying to make informed medical decisions in her daily life. These costs
should not be ignored. (3) We allow pregnant women to consent to unknown
risks on behalf of their fetuses in the medical context all the time. When doctors
prescribe drugs to treat illnesses in pregnant women, the prescription is almost
10
In this sense, pregnant women conduct a sort of
always off-label.o
experimentation on themselves-with risks similar to that of IRB research, but
without any of the safeguards."'
Though the fetus is unable to consent, its interests in this context cannot be
regarded as wholly separate from the pregnant woman's interests. The fetus's
welfare is directly attached to the welfare of the woman: "Physically, the woman
and fetus are interconnected, the health or illness of one influencing the same in
the other. More than that, the future wellbeing of each is, in the usual case,
deeply connected. Children are affected by their parents' health and happiness;
parents are affected by their children's well-being."' 1 2 Consider the examples
discussed above: delaying medical treatment for HIN1 or appendicitis in
pregnant women not only harmed the woman, but the fetus as well.1 3 Unhealthy
pregnant women increase the likelihood of health complications for their fetuses
and untreated illness can cause miscarriages.1 4 For instance, depression in
pregnancy is correlated with low birth weight," 5 pre-term delivery, low Apgar
score, fetal growth retardation, neonatal irritability, and behavioral problems." 6
Regardless, depression often remains untreated for fear of drug risks, even
though "this fear is not evidence-based, but rather a cautionary response
attributable to a lack of randomized controlled trials in pregnant women .... "7
Other examples include a higher incidence of fetal cardiac malformations if the

&

1 10. See The Second Wave, supra note 3, at 7.
111. This is different in the pediatric context, where off-label pediatric usage is less prevalent
because more drugs have been tested and approved by the FDA for use in children. "[I]n 2009,
more than 60 percent of the drugs used for both adults and children that were in the Physician's
Desk Reference-a drug information resource for physicians and other health professionals-had
specific information on pediatric use ..... Database Is One-Stop Resource on Kids' Medications,
U.S. FOOD & DRUG ADMIN. (May 22, 2012), http://www.fda.gov/ForConsumers/
ConsumerUpdates/ucm305040.htm. However, 91.2 percent of drug treatments approved between
1980 and 2000 did not have any human safety data on consumption during pregnancy. See Lo
Friedman, supra note 30, at 465.
112. The Second Wave, supra note 3, at 14.
113. See Lyerly, Mitchell, Armstrong, Harris, Kukla, Kuppermann & Little, supra note 49;
The Second Wave, supra note 3, at 12; see also Greenwood, supra note 3, at 268.
114. See The Second Wave, supra note 3, at 12; see also Little, Lyerly & Faden, supra note 3.
115. See A. S. Khashan, C. Everard, L. M. E. McCowan, G. Dekker, R. Moss-Morris, P. N.
Baker, L. Poston, J. J. Walker & L. C. Kenny, Second-Trimester MaternalDistress Increases the
Risk of Smallfor GestationalAge, 44 PsYcHoL. MED. 2799, 2806 (2014).
116. Alison Reminick, Stacy Cohen & Adrienne Einarson, Managing Depression During
Pregnancy, 9 WOMEN'S HEALTH 527, 529 (2013).
117. Id. at 527.
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woman has diabetes while pregnant," 8 higher risk of neurological complications
if the woman has a Cytomegalovirus infection while pregnant,1 19 higher risk of
low birth weight and preterm delivery if the woman has asthma while
pregnant,1 2 0 and higher risk of miscarriage and perinatal morbidity and mortality
if the woman has various autoimmune diseases, such as lupus, anti-phospholipid
syndrome, multiple sclerosis, and type-one diabetes.1 21 Fetal and maternal
outcomes can be improved if these conditions are treated during pregnancy,1 22
though many physicians are reluctant to do so.
Given this correlation with the health of the pregnant woman and the health
of the fetus, it is unclear whether purported fetal-maternal conflict is legitimate
in most cases, or, at the very least, whether it is serious enough to justify
government interference. Though medical research is different from clinical
treatment, any health benefit achieved through medical research in the pregnant
woman could also improve the health outcomes in the fetus, despite potentially
exposing it to risks. The risks involved in permitting pregnant women to
participate in medical research are important and worth serious consideration,
but the reality is that fetal birth defects as a result of drug exposure are
uncommon.1 23 This insight is only more powerful given that these protective
regulations, which in practical effect ban pregnant women from research, harm
fetuses in the long run. When pregnant women choose to avoid medications
needed to treat illness, their health can worsen, which can also diminish their
fetuses' health outcomes. Conversely, if pregnant women consume physicianprescribed medications during their pregnancies that carry unknown dangers, this
could lead to fetal defects and cause future disabilities.1 24 If women had drugsafety information produced from clinical trials, maternal and fetal health would
118. See Avisa Tabib, Nooshin Shirzad, Sara Sheikhbahaei, Sara Mohammadi, Mostafa

Qorbani, Vahid Haghpanah, Farzaneh Abbasi, Shirin Hasani-Ranjbar & Ramin Baghaei-Tehrani,

&

Cardiac Malformations in Fetuses of Gestational and Pre GestationalDiabetic Mothers, 23 IRAN
J. OF PEDIATRICS 664, 666 (2013).
119. See Karen B. Fowler, Sergio Stagno, Robert F. Pass, William J. Britt, Thomas J. Boll
Charles A. Alford, The Outcome of Congenital Cytomegalovirus Infection in Relation to Maternal
Antibody Status, 326 NEw ENG. J. MED. 663, 663 (1992).
120. See Diego J. Maselli, Sandra G. Adams, Jay 1. Peters & Stephanie M. Levine,
Management of Asthma During Pregnancy, 7 THERAPEUTIc ADVANCES RESPIRATORY DISEASE 87,

88 (2014).
121. See Andrea T. Borchers, The Implications of Autoimmunity and Pregnancy, 34 J.
AUTOIMMUNITY J287 (2010).
122. See Reminick, Cohen & Einarson, supra note 116; Maselli, Adams, Peters & Levine
supra note 120, at 97; Borchers, supra note 121, at J296-97.
123. See REVIEWER GUIDANCE, supra note 3, at 2 ("Chemically induced birth defects,
including those associated with drug exposure, probably account for less than 1 percent of all birth
defects; few drugs are proven human teratogens at clinical doses. Of the thousands of drugs
available, only about twenty drugs or groups of drugs (most being anticonvulsants, antineoplastics,
or retinoids) are recognized as having an increased risk of developmental abnormalities when used
clinically in humans." (citation omitted)). Even thalidomide is not dangerous when prescribed at
the right time of pregnancy. Id.
124. See The Second Wave, supra note 3, at 10-11; Little, Lyerly & Faden, supra note 3.
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improve because physicians would know when to prescribe and when to avoid
medications in pregnancy. Though more information might not always provide
perfect guidance, it would permit pregnant women to make more informed
decisions based on their own values. Pregnant women should be trusted to
understand the relative risks of participating in research and to decide what is
best for themselves and their fetuses.
Finally, certain scholars have employed an autonomy-based critique of the
designation of a fetus as separate from the pregnant woman.1 25 Seeing the fetus
as a distinct patient has led some physicians to inappropriately prioritize fetal
health over maternal health to the detriment of both.1 26 Pregnant women should
be seen and respected for their own health beyond their capacity to create a fetal
environment. This requires physicians to focus on the woman as the patient; if
the fetus becomes the focus, the woman becomes lost in her pregnancy.
Although this criticism was made in the context of medical treatment, as
opposed to research, the point remains salient in the research context, where
pregnant women are denied the opportunity to benefit due to concerns about the
fetus:
First is the worry that such a designation [of a fetus as a patient]
may encourage a tendency to think of the fetus as separate from
the pregnant woman, obscuring the physical and social
relationship between pregnant woman and fetus, the ways that
maternal and fetal physiologies and welfare are linked, and
perhaps most problematically, the woman herself . . . . [T]he
designation of [the fetus as a] 'patient' may make it easier to think
about the pregnant woman herself as an environment rather than a
7
patient in her own right. 12
Denying pregnant women the ability to participate in medical research
solely because they are pregnant seriously limits their personal autonomy to
make their own choices. This should only be permitted when there is a strong
justification, which Subpart B lacks.
Rationales for excluding pregnant women from research-their
susceptibility to coercion, inherent vulnerability, or eagerness to prioritize their
own interests above their fetus's-are based on antiquated and harmful
stereotypes that should be eliminated. Society ought to grant pregnant women
the autonomy to make complicated risk calculations, even when those involve
potential fetal harm. Though the overwhelming majority of mothers would likely
only participate in research if they believed it could benefit both themselves and
their fetuses, this is not the only instance in which it might be ethical for
pregnant women to participate. For instance, there are times when a pregnant
125. Anne Drapkin Lyerly, Margaret Olivia Little & Ruth Faden, A Critique ofthe 'Fetus as
Patient,'8 AM. J. BIOETHICS 42 (2008).
126. See id. at 43.
127. Id (internal citation omitted).
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woman's needs are so great that it might be appropriate for her to participate in
medical research despite a likelihood that the fetus could be harmed.1 28 This is
true especially in the context of experimental therapy for life-threatening
conditions, where risks to the fetus should be balanced against the possibility of
the woman's death while pregnant (and the subsequent death of the fetus).
Ultimately, the IRB regulations that attempt to protect pregnant women and
their fetuses yield an odd result; in order to protect fetuses from the risks of
medical research, both fetuses and pregnant women are subjected to similar risks
through exposure to untested medications. By crafting regulations that have
systematically excluded pregnant women from medical research for their own
protection, the government created a system in which pregnant women are
routinely exposed to risks without any of the public health benefits. Protecting
people from this exact harm-the risks of untested drugs-is one of the reasons
the IRB system was created.1 29
Not only do these regulations permit pregnant women to assume the risks of
research without any benefits, they also manufacture bad science. Currently, the
best source of information on the risks of drugs is pregnancy exposure registries
and other post-approval research methods. 30 Pregnancy exposure registries
collect health information from pregnant women who consume drugs after FDA
approval; women enroll when they begin taking medications, before any
complications have arisen.131 If a complication with the medication does arise,
then the pregnant women report it to the registry.1 32 While these registries
provide needed information for guidance data-deprived population,' 33 and are the
most scientifically accurate post-approval monitoring device,1 34 the reliable
information they generate is limited. 35
FDA approval of a new drug is only based on randomized, double-blind,
placebo-controlled clinical trials-this high standard ensures that misleading

128. See Little, Lyerly & Faden,supra note 3, at 61-62.
129. About FDA, What We Do, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/aboutfdal
whatwedo/ (last updated Aug. 5, 2014).

130. 73 Fed. Reg. 30,831, 30,840-41 (proposed May 29, 2008) (to be codified at 21 C.F.R.
pt. 201) ("Therefore, human data concerning a drug's effect(s) on pregnant women and their
offspring almost never come from controlled clinical trials . . . . Sources that may contribute to an
evaluation of whether a drug increases the risk of developmental abnormalities include pregnancy
exposure registries, cohort studies, case-control studies, case series, and case reports.").
131. See Dianne L. Kennedy, Kathleen Uhl & Sandra L. Kweder, Pregnancy Exposure
Registries, 27 DRUG SAFETY 215, 217 (2004).

132. Id.
133. Id.; 73 Fed. Reg. at 30,839-41.
13 4. Id.
135. See Kennedy, Uhl & Kweder, supra note 131 (explaining the scientific limitations of
pregnancy exposure registries and identifying them as best used as a hypothesis-generating tool or
to identify major risks).
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information will not be produced as a result of bad study design. 136 If the FDA
believes that only this gold standard of clinical research can produce reliable
information, the agency should not sanctionl 37 pregnancy exposure registries as a
way to circumvent these reliable, clinical trials. Exposure registries are helpful
once reliable data exists, but they are insufficient to determine the baseline safety
standard.
The regulations governing ethics approval of medical research involving
pregnant women force pregnant women and doctors to make decisions based on
unreliable science: information generated by animal studies 38 or observation
through pregnancy exposure registries. 139 Both pregnant women and their fetuses
would benefit from the generation of safety data through reliable clinical trials
conducted in pregnant women.

II.
FDA LABELING REGULATIONS BIAS PREGNANT WOMEN AGAINST DRUG
CONSUMPTION

Once clinical trials are completed, a drug company will apply for FDA
approval. FDA approval is the final step before a drug can enter the market. The
FDA will only approve a new drug after clinical trials in human subjects
demonstrate that the drug is safe and effective. 140 Drugs are approved only for
specific uses and any off-label promotion by a drug company can be
prosecuted. 14 1 For this reason, the approval of a drug also involves the review of

136. 21 U.S.C. § 355(d)(1)-(5) (2012); 21 C.F.R. § 314.126 (2014); Suzanne White Junod,
FDA and Clinical Trials: A Short Story, U.S. FOOD & DRUG ADMIN., available at
http://www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm304485.htm
(last
updated
July, 7, 2014) ("Although several kinds of randomized controlled trial methodologies can be useful
to researchers and regulators, ultimately, it was the randomized, double-blinded, placebo
controlled experiment which became the standard by which most other experimental methods were
judged, and it has often subsequently been referred to as the "gold" standard for clinical trial
methodology.").
137. As discussed in Part II.B., the FDA's proposed and final labeling regulation includes a
focus on pregnancy exposure registries as a way to generate this new information. 73 Fed. Reg. at

30,839-41; 79 Fed. Reg. 72,064, 72,069 (proposed Dec. 4, 2014) (to be codified at 21 C.F.R. pt
201).
138. See infra note 190 for a discussion on the reliability of animal studies.
139. See supra notes 130-137.

140. 21 U.S.C. § 355(d) (2012).
141. U.S. Dep't of Justice Press Release, Inspections, Compliance, Enforcement, and
Criminal Investigations, FDA (Nov. 4, 2013), available at http://www.fda.gov/icecil
criminalinvestigations/ucm375816.htm ("Under the FDCA, a pharmaceutical company must
specify the intended uses of a drug in its new drug application to the FDA. Before approval, the
FDA must determine that the drug is safe and effective for those specified uses. Once the drug is
approved, if the company intends a different use and then introduces the drug into interstate
commerce for that new, unapproved use, the drug becomes misbranded. The unapproved use is
also known as an "off-label" use because it is not included in the drug's FDA-approved labeling.").
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its labeling to ensure that the label provides accurate information on risks and
42
promotes proper use. 1

Once a drug company has completed the necessary clinical trials, it submits
a New Drug Application ("NDA") to the FDA for approval. Many
considerations go into the FDA's decision whether to approve a drug. In addition
to reviewing the clinical data to ensure the drug is safe and effective, 143 the FDA
also regulates the labels that accompany drugs.144 It is important to note that any
information a company wants to include in marketing materials must be based
on approved product labeling as, "FDA-approved product labeling is the
foundation upon which all promotional information about a drug is based. In
other words, promotional labeling and advertising may not contain information
or claims not asserted in the FDA-approved product labeling."l 45
Under current regulations, all non-exempt drug labels must include
warnings specific to pregnant women.1 46 The regulations categorize drugs into
five pregnancy categories, each of which requires a different label to be placed
on the drug.1 47 The categories are based on available risk information. As clinical
data based on research in pregnant women is rare, risks established only through
research in pregnant animals often dictate the class to which the drug is
assigned.1 4 8 Due to substantial criticism of the current regulatory framework, the
FDA proposed new pregnancy labeling regulations in 2008 to modify its existing

142. 21 C.F.R. § 201.56-57 (regulating the labeling reviewed during the FDA approval
process). See MATTHEW BENDER & LAW JOURNAL PRESS, REGULATION OF PHARMACEUTICAL

MANUFACTURERS § 1.07(2)(a) & (3) (2012) (discussing the requirements of the approved product
labeling and their importance as the benchmark for what constitutes off-label use).

143. 21 U.S.C. § 355(d)(l)--(5).
144. The Federal Food, Drug and Cosmetic Act ("FDCA") defines label as a "display of
written, printed, or graphic matter upon the immediate container of any article . . . ." Federal Food,
Drug, and Cosmetic Act, 21 U.S.C. § 321(k) (2012). "The term 'immediate container' does not
include package liners." Device Labeling: Introduction to Medical Device Labeling, Label vs.
&
DRUG
ADMIN.,
http://www.fda.gov/MedicalDevices/
Labeling,
U.S.
FOOD
DeviceRegulationandGuidance/Overview/DeviceLaDevice/ (last updated Jan. 8, 2013). Labeling
has been further defined by FDA regulations, which created a list of items that fit within the

definition of labeling. 21 C.F.R. § 202.1(1)(2) (2014) ("Brochures, booklets, mailing pieces,
detailing pieces, file cards, bulletins, calendars, price lists, catalogs, house organs, letters, motion
picture films, film strips, lantern slides, sound recordings, exhibits, literature, and reprints and
similar pieces of printed, audio, or visual matter descriptive of a drug and references published (for
example, the 'Physicians Desk Reference') for use by medical practitioners, pharmacists, or
nurses, containing drug information supplied by the manufacturer, packer, or distributor of the
drug and which are disseminated by or on behalf of its manufacturer, packer, or distributor are
hereby determined to be labeling as defined in section 201(m) of the act.").
145. BENDER & LAW JOURNAL PRESS, supra note 142, at § 107(2)(a).
146. See 21 C.F.R. § 201.57(c)(9)(i) (2014). Exempt labels are those where the drug is
"absorbed systemically" and "is not known to have a potential for indirect harm to the fetus."

147. See § 201.57(c)(9)(i)(A)(l)H5).
148. Id-
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regulations. 149 The final rule came out in December 2014, and took effect on
June 30, 2015.150 However, the final rule will not be fully implemented until
2020.'1' The next Part explores the previous regulations and the new, final
pregnancy labeling regulations. It concludes that the previous regulations were
inadequate, and though the new regulations improve on key issues, they still fail
to treat pregnancy labeling consistently with other labeling regulations, such as
pediatric labeling.
A. PreviousPregnancyLabelingRegulations PrioritizedFetalHarm over
MaternalHealth, Failedto PresentNeutral Information, and Requiredthe
Presentationof UnreliableData
Previous pregnancy labeling regulations are currently being phased out.
However, because the final rule will not be fully implemented until 2020,
understanding the previous regulations is highly relevant to understanding the
current and ongoing changes in the law. This is especially true in light of the fact
that many of the changes to the pregnancy labeling regulations result from
criticisms of the previous regulations. The requirement to include pregnancy
warnings on the labeling of drugs is found in two identically worded provisions
of the Code of Federal Regulations. 152 21 C.F.R. § 201.57(c)(9)(i) governs drugs
submitted for FDA approval after 2006, while 21 C.F.R. § 201.80(f) governs
drugs submitted to the FDA for approval before 2006.153 The regulations
required that all drugs "not absorbed systemically and .... not known to have a
potential for indirect harm to the fetus," 1 54 must have one of five warning
labels. 155 The available risk information regarding a certain drug correlates with
a class category: A, B, C, D, or X. (See Table One below.) All drugs in a given
class had to contain the assigned language related to the respective sub-category
as part of their labeling.1 56

149. Content and Format of Labeling for Human Prescription Drug and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201).
150. 79 Fed. Reg. 72,064 (proposed Dec. 4, 2014) (to be codified at 21 C.F.R. pt. 201).

151. Id. at 72,095-96.
152. See 21 C.F.R. § 201.57(c)(9)(i) (2014) (governing drugs submitted to the FDA for
approval after 2006); Specific Requirements on Content and Format of Labeling for Human
Prescription Drug and Biological Products; Older Drugs Not Described in § 201.56(b)(1), 21
C.F.R. § 201.80(f) (2012) (governing drugs submitted to the FDA for approval prior to 2006). The
two regulations are identical but for the dates of the drugs they govern. In later citations I will only

cite to 21 C.F.R. § 201.57(c)(9)(i) since this is the regulation related to post-2006 drugs.
153. Id.

154. 21 C.F.R. § 201.57(c)(9)(i).
155. § 201.57(c)(9)(i)(A)(I)-(5).
156. § 201.57(c)(9)(i)(A).
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Table One: Description of the Pregnancy Labeling Requirements in Effect
from 2006 - 2015
Class Available Risk Evidence
Required Warning
1 57

Adequate and well-controlled studies in
pregnant
women
have
failed
to
demonstrate a risk to the fetus in the first
trimester of pregnancy (and there is no
evidence of a risk in later trimesters)

Studies in pregnant women have not
shown that (name of drug) increases the
risk
of
fetal
abnormalities
if
administered during the first (second,
third, or all) trimester(s) of pregnancy.
If this drug is used during pregnancy,
the possibility of fetal harm appears
remote. Because studies cannot rule out
the possibility of harm, however, (name
of drug) should be used during
pregnancy only if clearly needed.

B 15 8

Animal reproduction studies have failed to
demonstrate a risk to the fetus and there
are no adequate and well-controlled
studies in pregnant women

Reproduction
studies have
been
performed in (kind(s) of animal(s)) at
doses up to (x) times the human dose
and have revealed no evidence of
impaired fertility or harm to the fetus
due to (name of drug). There are,
however, no adequate and wellcontrolled studies in pregnant women.
Because animal reproduction studies are
not always predictive of human
response, this drug should be used in
pregnancy only if clearly needed.
Reproduction studies in (kind(s) of
animal(s))
have shown (describe
findings) at (x) times the human dose.
Studies in pregnant women, however,
have not shown that (name of drug)
increases the risk of abnormalities when
administered during the first (second,
third, or all) trimester(s) of pregnancy.
Despite the animal findings, it would
appear that the possibility of fetal harm
is remote, if the drug is used during
pregnancy. Nevertheless, because the
studies in humans cannot rule out the
possibility of harm, (name of drug)
should be used during pregnancy only if
clearly needed.

A

Animal reproduction studies have shown
an adverse effect (other than decrease in
fertility), but adequate and well-controlled
studies in pregnant women have failed to
demonstrate a risk to the fetus during the
first trimester of pregnancy (and there is
no evidence of a risk in later trimesters)

C 159

Animal reproduction studies have shown
an adverse effect on the fetus, there are no
adequate and well-controlled studies in
humans, and the benefits from the use of
the drug in pregnant women may be
acceptable despite its potential risks

(Name of drug) has been shown to be
teratogenic (or to have an embryocidal
effect or other adverse effect) in
(name(s) of species) when given in
doses (x) times the human dose. There
are no adequate and well-controlled
studies in pregnant women. (Name of

157. § 201.57(c)(9)(i)(A)(1).
158. § 201.57(c)(9)(i)(A)(2).
159. § 201.57(c)(9)(i)(A)(3).
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There are no animal reproduction studies
and no adequate and well-controlled
studies in humans

D1 60

X 16 1

If there is positive evidence of human fetal
risk based on adverse reaction data from
investigational or marketing experience or
studies in humans, but the potential
benefits from the use of the drug in
pregnant women may be acceptable
despite its potential risks (for example, if
the drug is needed in a life-threatening
situation or serious disease for which safer
drugs cannot be used or are ineffective)
Studies in animals or humans have
demonstrated fetal abnormalities or there
is positive evidence of fetal risk based on
reports
from
reaction
adverse
investigational or marketing experience, or
both, and the risk of the use of the drug in
a pregnant woman clearly outweighs any
possible benefit (for example, safer drugs
or other forms of therapy are available)

Vol. 39:45

drug) should be used during pregnancy
only if the potential benefit justifies the
potential risk to the fetus.
Animal reproduction studies have not
been conducted with (name of drug). It
is also not known whether (name of
drug) can cause fetal harm when
administered to a pregnant woman or
can affect reproduction capacity. (Name
of drug) should be given to a pregnant
woman only if clearly needed.
(Name of drug) can cause fetal harm
when administered to a pregnant
woman. (Describe the human data and
any pertinent animal data.) If this drug
is used during pregnancy, or if the
patient becomes pregnant while taking
this drug, the patient should be apprised
of the potential hazard to a fetus.

(Name of drug) may (can) cause fetal
harm when administered to a pregnant
woman. (Describe the human data and
any pertinent animal data.) (Name of
drug) is contraindicated in women who
are or may become pregnant. If this
drug is used during pregnancy, or if the
patient becomes pregnant while taking
this drug, the patient should be apprised
_ of the potential hazard to a fetus.

These labeling instructions are inadequate for many reasons, the most
significant being that they are unnecessarily precautious. Even for Class A
drugs-drugs in which clinical trials in pregnant women and pregnant animals
have failed to demonstrate harm 16 2 -the labeling must include the following

warning: "Because studies cannot rule out the possibility of harm, however,
(name of drug) should be used during pregnancy only if clearly needed."

63

Even

if a drug is able to gain Class A status-a status only 0.7% of drugs hold'64-the
drug label must contain a warning against taking the drug unless doing so is
clearly needed. Such a precaution is unjustified. The risk of harm associated with

drug consumption can never be conclusively ruled out whether or not one is
pregnant. Not only do all drugs carry some side effects that are not worth
enduring unless the drug is needed, but also it is not unheard of for FDA-

160. § 201.57(c)(9)(i)(A)(4).
161. § 201.57(c)(9)(i)(A)(5).
162. § 201.57(c)(9)(i)(A)(I).

163. Id
164. See Friedman,supra note 65

r
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approved drugs, which have undergone rigorous clinical trials in human subjects,
to be removed from the market due to serious safety concerns.165 Yet, despite the
inability of the FDA to conclusively rule out potential drug harm, the FDA does
not require such cautious labeling in non-pregnancy contexts. If it did, every
pharmaceutical would be required to contain a warning label that discouraged
drug consumption unless clearly needed, as all drugs have risks that are not
worth enduring without an indication that the drug is needed. Because drug
consumption should always be avoided unless clearly needed, the language on
the pregnancy labeling was wholly unnecessary. No doctor would prescribe a
medication and subject her patient to risk unless the patient needed the drug.
While this general practice is not unique to pregnancy, pregnancy labeling
regulations are the only place in which such a warning is required,1 66 indicating
that the FDA is singling out pregnant women by encouraging them to avoid
needed medications.
A comparison with the pediatric labeling requirements underscores how
unusual and paternalistic pregnancy warnings are. Children can also have
different drug responses than the general population.1 67 Therefore, like
medication intended for pregnant women and fetuses pediatric drug consumption
requires unique labeling.' 68 As in pregnant women, testing drugs in children has

also been very difficult to accomplish due, in large part, to the regulations
guiding IRB approval in this population.1 69 Because children are also considered
vulnerable, research on them must meet the more extensive requirements of

another subpart (Subpart D) in addition to the baseline requirements found in
Subpart A.'7 0 This has led to a similar lack of information on drug safety in
children.' 7' Unlike the pregnant population, however, this was viewed as "poor
165. See, e.g., Vioxx Recall Information, DRUGWATCH, http://www.drugwatch.com/vioxx/
recall/ (last visited July 11, 2013); Drug Recalls, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
Drugs/DrugSafety/DrugRecalls/default.htm (last visited Oct. 15, 2014); Sequence of Events with
VIOXX, Since Opening ofIND, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ohrms/dockets/ac/
05/briefing/2005-4090Bl_04_E-FDA-TAB-C.htm (last visited Dec. 19, 2014).
166. See generally § 201.57.
167. See Drug Research and Children, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
Drugs/ResourcesForYou/Consumers/ucml43565.htm (last visited Oct. 19, 2014) (citing a
physician explaining that children are not simply "small adults"); Children, FDA Basics, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/aboutfda/transparency/basics/ucm319792.htm (last
visited November 2, 2014) (explaining that children's bodies break drugs down differently than
adults).
168. See Drug Research and Children, supra note 167 (discussing how increasing clinical
trials testing drugs' effects on children has resulted in changing labeling information regarding
appropriate dosing for children).
169. See Additional Protections for Children Involved as Subjects in Research, 45 C.F.R. §

46.401-09 (2013).
170. Id.
171. See Donna R. Rivera & Abraham G. Hartzema, Pediatric Exclusivity: Evolving
Legislation and Novel Complexities within Pediatric Therapeutic Development, 48(3) ANNALS OF
PHARMACOLOGY 369, 371 (2013) (posing hypotheticals as to why clinical trials in children are rare
with the consequence of there being a lack of information on drug safety in children).
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public policy," and Congress acted to fix this problem through a new provision
of the Food and Drug Administration Modernization Act ("FDAMA"), discussed
in more depth below.1 72 While this legislation improved the problem
significantly,1 7 3 some approved drugs still lack pediatric-risk information and the
FDA at times faces similar difficulties in requiring pediatric warnings without
reliable data. Pediatric labeling bears several distinctions from pregnancy
labeling. Pediatric drugs are not placed into classes, and the contents of pediatric
labels are much less cautious. 174 Unlike pregnancy labeling, these regulations
simply note that when clinical trials have been conducted in the pediatric
population that support a specific pediatric indication, that information must be
included under the "Indications and Usage" section and appropriate pediatric
dosage information must be given under the "Dosage and Administration"
section.'75 While any clinical findings of risk must be provided in the "Pediatric
Use" subsection on the labeling,1 76 there is no requirement that the labeling must
include a blanket warning to abstain from consumption if possible. 77
Furthermore, when no safety information exists in this population, the
warning required by the FDA still does not encourage avoidance of these drugs.
Instead, the following warning must be given: "Safety and effectiveness in
pediatric patients have not been established." 78 Even if pediatric studies have
demonstrated a potential for harm in the pediatric population, the FDA does not
require a warning against drug consumption. These risks are treated similarly to
risks established for healthy adults-they must simply be noted in the
"Contraindications" or "Warnings and Precautions" sections.1 79 In other words,
the FDA permits drugs that are known to be risky to children to contain less
precautious labeling than drugs tested in pregnant women without any
demonstration of risk. This kind of overprotective language found in the

172. Id. at 370 (explaining the patent extension incentive offered to pharmaceutical
companies by the FDAMA if they conducted FDA-approved pediatric trials according to certain
standards). This provision is discussed in greater depth infra Part Ill.
173. Id at 375. ("This legislation has been successful because the FDA reports that 425
pediatric studies have been conducted as of December 2012. This speaks well to the successful
efforts of the program to increase pediatric medication knowledge.").
174. Compare 21 C.F.R. § 201.57(c)(9)(iv) (2014) (labeling requirements for pediatric risk),
with 21 C.F.R. § 201.57(c)(9)(i) (labeling requirements for fetal risk).

175. § 201.57(c)(9)(iv)(B).
176. Id. ("The 'Pediatric use' subsection must cite any limitations on the pediatric indication,
need for specific monitoring, specific hazards associated with use of the drug in any subsets of the
pediatric population (e.g., neonates), differences between pediatric and adult responses to the drug,
and other information related to the safe and effective pediatric use of the drug.").

177. Id.
178. § 201.57(c)(9)(iv)(F).
179. Id. ("If the drug product contains one or more inactive ingredients that present an
increased risk of toxic effects to neonates or other pediatric subgroups, a special note of this risk
must be made, generally in the 'Contraindications' or 'Warnings and Precautions' section.").
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pregnancy labeling cannot be found anywhere else in the FDA's labeling
regulations.s0
The previous pregnancy labeling regulations also painted an incomplete
picture for readers in that they focused exclusively on fetal (as opposed to
maternal) risks from drug consumption.' 8' The regulations encouraged pregnant
women to avoid drugs and failed to present information on the risks associated
with drug avoidance.1 82 When an unknown, or under-evaluated, risk exists for
the pregnant woman herself, the FDA did not require any additional precautions,
and women were left with little information regarding their own health risks.1 83
Given that pregnant women can also have an abnormal response to drugs and
lack information on how their own bodies will process them,'" these regulations
were inappropriately lopsided. Warnings for fetuses are much more protective
than those for children;' yet pregnant women, who are also susceptible to
increased drug risks, received no warnings for their own safety.1 86 Pregnant
women are therefore under-warned about risks to themselves, and over-warned
about risks to their fetus.
This recommendation to avoid drug consumption might be more reasonable
if there were no risks associated with drug avoidance. As explored in Part I,
however, this excess caution can be very dangerous to women and, by
consequence, their fetuses.' 87 Despite this known harm, the current pregnancy
labeling regulations do not display any information about the potential harm of
avoiding needed medications to balance the uniquely precautious warnings. 8 8
Risk information on avoiding medication is necessary in this context to balance
out the overly cautious labeling required by the FDA. After reading warning
labels, pregnant women may be left with the impression that taking medications
could be risky, while avoiding medications will be safe. Pregnant women
deserve all available information to make well-informed decisions. This onesided story is another example of how the regulations prioritize fetal health while
ignoring the pregnant woman. With all available information, many women
would continue to choose drug avoidance; yet failing to provide women with this
data inappropriately biases decision-making.
The final criticism of the previous pregnancy labeling regulations explored
in this Part is the use of animal data on warning labels. While animal studies are
180. See § 201.57.
181. § 201.57(c)(9)(i).
182. Id
183. See id.
184. See The Second Wave, supra note 3, at 8-9.
185. Compare § 201.57(c)(9)(i) (labeling requirements for fetal risk), with § 201.57(c)(9)(iv)
(labeling requirements for pediatric risk).
186. § 201.57(c)(9)(i).
187. See supra Part lB.; The Second Wave, supra note 3, at 9-13; Little, Lyerly & Faden,
supranote 3.
188. § 201.57(c)(9)(i).
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included in all five pregnancy labels, the warning required for Class B drugs
provides the best example of how oddly such information is displayed:
Reproduction studies in (kind(s) of animal(s)) have shown
(describe findings) at (x) times the human dose. Studies in
pregnant women, however, have not shown that (name of drug)
increases the risk of abnormalities when administered during the
first (second, third, or all) trimester(s) of pregnancy. Despite the
animal findings, it would appear that the possibility of fetal harm
is remote, if the drug is used during pregnancy. Nevertheless,
because the studies in humans cannot rule out the possibility of
harm, (name of drug) should be used during pregnancy only if
clearly needed. 189

Despite clinical studies in pregnant women indicating a lack of harm, the
warning had to have included contradicting animal studies, which are often a bad
predictor of a human drug response.1 90 Perplexingly, the animal data is displayed
before human data.
One might question the use of any animal studies on drug labels. Animal
studies have never been considered highly predictive,191 and indeed, the FDA
requires human clinical trials before drug approval. 192 For instance, when a drug
lacks safety information in the pediatric context, the FDA does not mandate that
animal information be used in lieu of that data.1 93 Instead, they require that the
label indicate that human studies have not been performed and thus risk
information is unavailable.1 94 Compare this to the pregnancy context, where 88.7
percent of drugs approved by the FDA between 2003 and 2012 contained
labeling based only on animal data.1 9 5

189. § 201.57(c)(9)(i)(A)(2) (Pregnancy category B).
190. The lack of clear predictability of animal studies in animals has long been demonstrated.
See Gideon Koren, Anne Pastuszak & Shinya Ito, Drugs in Pregnancy, 338 NEw ENG. J. MED.
1128, 1131 (1998); Niall Shanks, Ray Greek & Jean Greek, Are Animal Models Predictivefor
Humans?, 4 PHIL. ETHICS & HUMAN. MED. 2 (2009); Wendy E. Wagner, Choosing Ignorance in
the Manufacture of Toxic Products, 82 CORNELL L. REv. 773, 778-79 (1997); see also Robert
Brent, Utilization of Animal Studies to Determine the Effects and Human Risks of Environmental
Toxicants (Drugs, Chemicals, and Physical Agents), 113 PEDIATRICS 984, 986 (2004) (explaining
that animal studies are helpful in predicting a drug's response in humans, but that data from a
range of other investigative approaches is required to make accurate predictions).
191. See supra text accompanying note 190.
192. Content and Format of Labeling for Human Prescription Drug and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,840-41 (proposed
May 29, 2008) (to be codified at 21 C.F.R. pt. 201). If these studies were sufficient, the FDA
would not require extensive tests in humans.

193. See § 201.57(c)(9)(iv).
194. Id
195. See Maryann Mazer-Amirshahi, Samira Samiee-Zafarghandy, George Gray & Johannes
N. van den Anker, Trends in Pregnancy Labeling and Data Quality for US-approved
Pharmaceuticals,AM. J. OBSTETRICS & GYNECOLOGY, June 7, 2014, at I.e4.
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Perhaps in the pregnancy context, requiring animal data is justified due to an
overwhelming dearth of information, which may be less true of the pediatric
context given various reforms discussed in Part III of this article. While this
might explain the use of animal data when human data is unavailable, it is
inappropriate and confusing to use animal data when contradicting human
studies exist. Human data is more reliable and should always trump animal
studies.1 96 This is especially pronounced for experiments on pregnant animals,
where "drugs are tested in animals at doses which exceed the therapeutic dose in
humans, and certain animal species have different baseline rates of birth
defects." 97 Other problems include "findings in a single animal species that are
caused by unique drug metabolism or a mechanism of action thought not to be
relevant to humans." 98 This use of animal data in drug labeling is not seen
anywhere else in the labeling regulations.1 99
Overall, the current regulatory framework for pregnancy labeling fails to
warn pregnant women of risks to themselves, over-warns them about risks to
their fetuses, uses unreliable animal data to suggest risk, and fails to balance any
fetal risk with the maternal and fetal risk of avoiding needed medications. These
inadequacies demonstrate a unique lack of neutrality on behalf of the FDA. This
is not the first time that questions have arisen regarding the FDA's neutrality for
politically charged issues related to reproduction. Most recently, the FDA's
failure to approve the Plan B emergency-contraception pill for girls under
seventeen was struck down by courts as lacking scientific basis:
Because the Secretary's action was politically motivated,
scientifically unjustified, and contrary to agency precedent, it
cannot provide a basis to sustain the denial of the Citizen Petition
. . . . [T]he agency's decision cannot withstand any degree of
scrutiny, not only because of its unexplained failure to follow the
FDA policies discussed above but also because of its disregard for
the scientific evidence that the FDA had before it.2 00
This is noteworthy because under the Chevron doctrine, 201 Courts typically
defer to agencies' reasonable interpretations of statutory language.

196. See supra text accompanying note 190.
197. Greenwood, supra note 3, at 284.
198. Content and Format of Labeling for Human Prescription Drug and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,864 (proposed May

29, 2008) (to be codified at 21 C.F.R. pt. 201).
199. See § 201.57.
200. Tummino v. Hamburg, 936 F. Supp. 2d 162, 192 (E.D.N.Y. 2013)); see also Tummino
v. Torti, 603 F. Supp. 2d 519, 546 (E.D.N.Y. 2009) ("Indeed, the evidence strongly suggests that
even the decision to permit the OTC sale of Plan B to women over the age of 18 was made solely
to facilitate the confirmation of Dr. von Eschenbach as Commissioner of the FDA.").
201. See Chevron U.S.A., Inc. v. Natural Res. Def. Council, Inc., 467 U.S. 837, 844 (1984).
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B. The Insufficiency of the 2008 PregnancyLabeling Change Proposaland 2015
FinalRule
In May of 2008, after receiving substantial criticism of the current
pregnancy labeling, the FDA proposed to amend the regulations. 202 The proposal
was drastic. First, the FDA would cease to place drugs into categories. 203 After
noting that the categorization model is not used in any other context, the FDA
concluded that a narrative structure would be less confusing. 204 The FDA also
recognized the inadequacy of animal data and the need, expressed most
persuasively by the physician community, to have human data upon which to
base proper patient counseling about risks. 205 The proposed regulation's fix to
this problem, however, was to require that pregnancy exposure registry
information be placed prominently on the labeling. 206 The hope was that more
pregnant women would participate in these registries if participation information
were easily accessible. Taken together, the proposed pregnancy subsection
would include the following information in the order presented: "(1) Pregnancy
exposure registry information (if applicable), (2) a general statement about the
background risk of fetal developmental abnormalities, (3) a fetal risk summary,
(4) clinical considerations, and (5) data." 207 Furthermore, the FDA proposed that
all drugs include a pregnancy subsection, not just drugs that are absorbed
systemically and affect the fetus. 208
The final rule, which took effect on June 30, 2015, in large part codified the
proposals set out in 2008. As is customary, the final rule tweaked the language
found in the proposed rule and made some substantive changes, but kept the
main provisions intact. The main pregnancy label headings under the final rule
are the following: (1) Pregnancy Exposure Registry; (2) Risk Summary; (3)
Clinical Considerations; and (4) Data.209
The FDA's new labeling regulation is important. It makes great strides
toward clarity and is a good first step toward normalizing pregnancy labeling
with other kinds of FDA subpopulation labeling. This is especially true with the
removal of categories and the proposal to detail risk through the traditional
narrative style used by the FDA. 210 Of special note, the new regulation will
require a background risk statement to be placed on all drugs. 211 This

202. 73 Fed. Reg. 30,831 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt. 201).

203.
204.
205.
206.
207.
208.

73 Fed. Reg. 30,838.
Id
73 Fed. Reg. 30,840-41.
73 Fed. Reg. 30,839.
Id
Id

209. 79 Fed. Reg. 72,064, 72,101-02 (proposed Dec. 4, 2014) (to be codified at 21 C.F.R. pt.
201).

210. Id at 72,076
211. Id. at 72,101.
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requirement requires all labeling to include information on the baseline risk of
birth defect and miscarriage. 212 In light of the fifteen-to-twenty-percent risk of
spontaneous miscarriage, the 0.5-percent risk of stillbirth, and the 3.5-percent
risk of birth defect in any given pregnancy, 2 13 the FDA wanted pregnant women
to know that their pregnancy could have complications even if they avoided all
drug consumption. 214 The final rule requires the labeling to "state the percentage
range of live births in the United States with a major birth defect and the
percentage range of pregnancies in the United States that end in miscarriage,
regardless of drug exposure. If such information is available for the
population(s) for which the drug is labeled, it must also be included." 2 15 This is
vital information that encourages more informed decision-making-women
should know that even if they avoid all drugs, their fetus might still be born with
health problems. Furthermore, it might reduce any guilt pregnant women feel if
they have complications with their pregnancy after taking medications given that
their use of pharmaceuticals may not have been to blame.
Other significant improvements come under the "Clinical Considerations"
subheading. First, the fetal and maternal risks associated with untreated medical
conditions-i.e., avoiding needed drugs-would be indicated in the labeling: "If
there is a serious known or potential risk to the pregnant woman and/or the
embryo/fetus associated with the disease or condition for which the drug is
indicated to be used, the labeling must describe the risk."2 16 In the proposed rule,
the FDA supported including this information by referencing the health risks
associated with failure to treat medical conditions in pregnancy:
Of the 62 million women of childbearing age (15 to 44) in the
United States (Ref. 28), more than 9 million have chronic
conditions such as asthma, epilepsy, and hypertension (Ref. 29)
that require ongoing treatment with prescription medicines.
Failure to treat these conditions properly can have serious
consequences for pregnant women and fetuses. 217
This provision is a tremendous step toward helping women to understand
the risks to themselves and their fetus of avoiding needed drugs.
Another important change in the final rule is a requirement to list maternal
risks of drug consumption that are unique to pregnancy. 218 As discussed above,
pregnant women do not always process drugs in the same way as non-pregnant
adults. This provision will ensure that women are aware of the risks to their own

212. Id.

213. 73 Fed. Reg. 30,831, 30,839 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt.
201).
214. 73 Fed. Reg. 30,839.
215. 79 Fed. Reg. 72,101.

216. Id.
217. 73 Fed. Reg. 30,844.
218. 79 Fed. Reg. 72,101-02.
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health if they take a medication. 219 It also requires the labeling to state whether
or not there are available interventions to monitor or mitigate the risks of those
drugs, as well as whether the drug's dose, timing, and duration of exposure could
impact the maternal adverse reaction. 220 These changes demonstrate that the
FDA is concerned about the health impact of drugs on both the pregnant woman
and the fetus, which is an important and much-needed shift.
Finally, the regulations also require more data to be presented in the
labeling, and with greater detail. The fetal-risk evidence available for each drug
must be placed in a subsection entitled "Data" below other pregnancy
information. 22 1 The regulations also require a summary of this information in the
"Risk Summary" section. 222 Both will include a description of human, animal,
and pharmacological data (in that order). 223 Notably, human data demonstrating
that a drug is associated with a specific fetal developmental outcome must be
compared with the potential for that developmental outcome without the drug. 224
The risk summary must also indicate when there is no human risk data
available. 225 Finally, the new regulations have removed any blanket warning not
to take the drug. 226 Taken together, these changes will improve the clarity of the
evidence presented to women and remove unnecessary, fear-inducing language.
While these new regulations represent a significant step forward, they
include notable failures. The main one is that the regulations will continue to
require all known animal data to be placed on the labeling, even when human
data is available, and the animal data is low quality. 227 The new regulation goes
even further than the prior regulation in that it also requires pharmacology data
to be displayed on the pregnancy label. 22 8 Though any human data must be
displayed first, 229 human data is largely unavailable. Animal and pharmacology
data is required in the Risk Summary Section and animal data is also required in
the Data Section.230
Many comments to the proposed rule argued that animal data should not be
included on FDA labels at all. The FDA received eleven comments (fifteen
percent of the seventy-two comments 23 1 it received in total) "primarily from

219. Id.

220.
221.
222.
223.

Id.
79 Fed. Reg. 72,102.
Id.
Id

224. Id

225. Id
226. See id. at 72,101-02.
227. Id at 72,102; see also discussion supra Part II.A.

228. 79 Fed. Reg. at 72,064; 72,069 1.
229. Id. at 72,101.
230. Id, at 72,101-02.
231. Id. at 72,071
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toxicologists, teratologists, and organizations representing toxicologists and
teratologists . . . expressing strong disagreement with the proposal to use risk
statements to characterize animal data." 232 Of these eleven,
Several comments stated that the proposal to use category
a
data
demonstrates
animal
describe
to
language
experimental
misunderstanding of the function and meaning of
animal studies. These comments explained that although animal
data can identify the potential of a therapeutic agent to cause
developmental toxicity, it cannot give rise to an estimate of the
233
probability of human harm.

The FDA did not respond directly to this criticism, but noted simply that
"when animal studies do not meet current standards for nonclinical
developmental toxicity studies or when there are no animal data, the labeling
must so state." 234 This response begs the question: if the studies do not meet
current standards, then why should they be included on the labeling at all? This
is especially true, given that in the FDA's draft guidance for industry-released
on the same day as the final rule-the FDA admits that it is not "possible to
conclude that a drug causes an increased risk of a particular type of
developmental effect based on animal data alone."

235

The inclusion of high-

quality animal data is itself controversial, but including poor quality animal data
236
on FDA drug labels is highly out of touch with the FDA's mission. At the very
least, the FDA should limit the presence of this data to only the most predictive
animal studies.
Moreover, the regulations go further and also require the pregnancy section
of drug labels to include pharmacology information if the drug has a wellunderstood mechanism of action that may result in adverse developmental
outcomes. 237 The draft guidance for industry explains that examples to be
included in this section involve drugs that interfere with DNA replication, induce
23
cell death, or alter transmissions in major neurotransmitters. 8 Because most
drugs lack human data, pregnancy labels will be filled predominately with
animal and pharmacology data. Though this data is relevant in constructing
human clinical trials, as explained above, it is not reliably predictive of the

232. Id. at 72,084.
233. Id.

234. Id
235. U.S. FOOD & DRUG ADMIN., PREGNANCY, LACTATION, AND REPRODUCTIVE POTENTIAL:
LABELING FOR HUMAN PRESCRIPTION DRUG AND BIOLOGICAL PRODUCTS - CONTENT AND FORMAT,
GUIDANCE FOR INDUSTRY 8 (2014) [hereinafter PREGNANCY, LACTATION, AND REPRODUCTIVE
http://www.fda.gov/downloads/Drugs/
at
available
POTENTIAL],
GuidanceComplianceRegulatorylnformation/Guidances/UCM425398.pdf.
236. See supra Part I.A for a discussion of the use of animal data on drug labels.

237. 79 Fed. Reg. at 72,101-02.
238. PREGNANCY, LACTATION, AND REPRODUCTIVE POTENTIAL, supra note 235, at 9.
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human drug response. For this reason, it is unclear whether such information can
form the basis of informed decision-making, or has any place on drug labels.
The regulations for animal data require the following information be
displayed: "Types of studies, animal species, dose, duration and timing of
exposure, study findings, presence or absence of maternal toxicity, and
limitations of the data. Description of maternal and offspring findings must
include dose-response and severity of adverse developmental outcomes." 2 39
Given that all of this information would need to be displayed about every animal
study conducted, these labels will become large and complicated. The presence
of a number of such studies might leave pregnant women who lack scientific
training with a false impression even when the animal data is of a relatively high
quality. When there are many low-quality animal studies on a label, pregnant
women might not grasp the data's comparative unreliability.
The FDA continues to promote the use of animal data on its labels despite
an awareness of its shortcomings. For instance, in the new regulations the
agency acknowledges the importance of human data: "[T]he positive and
negative predictive values of animal studies for humans are often uncertain. In
screening for drug-induced fetal effects, animal models can be misleading by
suggesting associations that ultimately turn out to be false positive or false
negative in humans." 240 The agency even understands the consequences of
failing to generate this information as it stated:
Most health care providers are not able to translate animal
reproductive toxicity data into an accurate assessment of human
teratogenic risk. Thus, in the absence of human data, it is difficult
for health care providers to adequately counsel patients about the
risks of drug use in pregnancy. Without adequate counseling,
women may decide to take steps to avoid becoming pregnant
while on needed drug therapy, to forego needed drug therapy
while pregnant, or to terminate pregnancies. 24 1
In an attempt to generate more human data, the agency endorses pregnancy
exposure registries as a solution to the problem. 242 The regulations require
pregnancy exposure registry information, if available, to be placed on drug
labeling to encourage consumer involvement. 243 As discussed above, however,
post-market-approval studies generate much less reliable data than human
clinical trials. 244 In the final rule, the FDA acknowledges this fact. One

239. 79 Fed. Reg. at 72,101-02.
240. 73 Fed. Reg. 30,831, 30,841 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt.
201).
241. Id.
242. 73 Fed. Reg. 30,839, 30,863-67; 79 Fed. Reg. 72,101.
243. 79 Fed. Reg. 72,101.
244. See Kennedy, Uhl & Kweder, supra note 131 (explaining the scientific limitations of
pregnancy exposure registries and identifying them as best used as a hypothesis-generating tool or

Imaged with Permission of N.Y.U. Review of Law & Social Change

2015

ENCOURAGING M TERNAL SACRIFICE

81

commenter noted "sufficient data must be based on large-scale epidemiologic
studies or clinical trials, and cannot be based on pregnancy registries or case
reports/series requiring further evaluation." 245 The FDA responded that it
"recognizes that because retrospective voluntary adverse event reporting may be
biased and incomplete, spontaneous reports cannot rule in or out a causal
relationship between drug exposure and clinical outcome." 246 The agency,
however, ultimately concluded that pregnancy registries could provide valuable
information. Though this post-approval data does have some value, the FDA
generally only uses it to monitor risks, not to generate first-in-population data. 247
The FDA's requirement that the labeling promote these registries condones offlabel drug consumption by pregnant women despite known risks. 248 In this way,
the FDA's solution to the lack of information in pregnancy is inconsistent with
its general practice.
C. Consequences of the FDA Pregnancy Labeling Regulations
Pregnancy labeling of drugs is very important; both women and doctors
refer to it when deciding if they should consume or prescribe medications during
pregnancy. 249 The way that data is displayed, and whether it has a cautious tone,
will impact decision-making. Current FDA regulations are inadequate. Even
when human data exists and fails to demonstrate risk, the regulations encourage
precaution and restraint. 250 This restraint is encouraged despite the fact that overcaution with drug consumption can be harmful. 25 1 Finally, the risks to pregnant

women themselves are not included anywhere in the labeling despite genuine
risks for their safety. 252 This sends the message that the only legitimate factors in
drug consumption are fetal risk and benefit.
The new regulations are an important improvement. Not only are they more
descriptive and informative, but they also provide greater insight into the
maternal and fetal risks associated with pregnant women's avoiding and

to identify major risks); see also Junod, supra note 136, at 2 ("Although simple observation may
provide a starting point for medical study, however, experience has shown that it is rarely efficient
at advancing medical knowledge."). The same article also noted the evolution of clinical trials to
culminate in the double-blind, placebo controlled trail as the most reliable, gold-standard method
of generating reliable data. Id.
245. 79 Fed. Reg. at 72,081.
246. Id. at 72,082.
247. See Kennedy, Uhl & Kweder, supranote 131.
248. See supra Part .B for a discussion of the risks associated with pregnant women
consuming medications without data on their safety or effectiveness.

249. 73 Fed. Reg. 30,831, 30,841 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt.
201).
250. See Table One.
251. See Part lB.
252. See Table One.
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consuming needed medications. 253 They remove any unnecessary blanket
warnings to avoid drug consumption and include information about background
risk.2 54 They fail, however, to address the main problem: a lack of data. The
regulations encourage pregnancy exposure registries to generate human data,
which are less informative than tests on human subjects.

25 5

The agency also

continues to include animal and pharmacologic data, even though this is not used
for any other subpopulation and has unclear predictive value for humans. 256
Pregnancy labeling is a unique FDA practice. Though providing access to data is
extremely important, there should be a focus on access to reliable data. More
access to unreliable data might not serve to help women make informed
decisions.
III.
AN APPROACH TOWARD IMPROVING ACCESS TO DRUG RISK INFORMATION IN
PREGNANT WOMEN

Protecting pregnant women from the risks of drug consumption will involve
a lot of moving parts. First, it will involve altering the IRB regulations to ensure
that IRBs stop effectively banning pregnant women from medical research.
Because pregnant women are not more susceptible to coercion, 257 they should be
treated as other adults and allowed to participate in ethical medical research as
defined by 45 C.F.R. § 46.111 (a)-(b). As discussed in greater depth below, 45
C.F.R. § 46.111(b) will ensure that the IRB accounts for the uniqueness of the
fetal-woman relationship in a way that is specific to a given protocol.
Though removing Subpart B would make it less burdensome to get clinical
trials involving pregnant women approved by IRBs, drug companies might still
avoid clinical trials in pregnant women. If pharmaceutical companies are not
forced to generate this information, and they do not expect to benefit financially
from providing it, they will continue to avoid conducting these clinical trials
despite the removal of regulatory hurdles. Thus, financial incentives should be
developed to encourage drug companies to invest in this data production. This
Part argues that providing pharmaceutical companies with a period of regulatory
exclusivity if they conduct clinical trials in pregnant women is the best financial
incentive to promote this needed research. This was successfully accomplished
in the pediatric context. Finally, once these financial obstacles are removed and
this data is generated, the FDA labeling guidelines should be altered to rely
solely on human data, treating pregnant women as the agency treats other

253. 79 Fed. Reg. 72,064, 72,101-02 (proposed Dec. 4, 2014) (to be codified at 21 C.F.R. pt.
201).

254. Id. See Table One for the past regulations and the blanket warnings that were required.
255. Id.
256. Id.
257. For reference to the classification of pregnant women as a "vulnerable" group, see 45

C.F.R. § 46.111 (a)(3). For a critical discussion of this classification, see Part I.C.
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populations. In this scenario, the pregnancy labeling requirements would look
more like the pediatric labeling requirements and foster informed decisionmaking for pregnant women.
A. Eliminate SubpartB and EncourageIRB Members to View Pregnant Women
as Complex, Not Vulnerable
A critical step in any comprehensive reform would include amending the
regulations on ethical human subjects research. Regulating research in pregnant
women under the same framework used for children and prisoners is
unnecessary and unjustified. Pregnant women are no more vulnerable than other
adults to coercion.258 They are capable of weighing the costs and benefits to
themselves and their fetuses in deciding whether to participate in research. While
some people may be uncomfortable with the idea of pregnant women consuming
drugs with unknown risk profiles, the alternative is to expose many more
pregnant women to similar risks without the protections IRBs provide when they
review and approve research protocols. The risks pregnant women endure in the
clinical setting do not benefit society by providing scientific knowledge and, if
they produce any data at all, it is much less reliable than data from clinical
trials.25 9
Many bioethicists have argued that research on pregnant women needs to
move from a presumption of exclusion to a presumption of inclusion. 260 In this
framework, IRBs would have to justify every decision to exclude pregnant
women from clinical trials, whereas now, they feel they must justify every
decision to include them. 261 This recommendation must be incorporated into IRB
practice. A recent article in Women 's Health Issues contains a further proposal
on how to alter the IRB regulations. 262 The authors recommend reclassifying
pregnant women as "complex" rather than "vulnerable," and creating a special
ethical framework to accompany the new title. 263 This recommendation is

helpful, but ultimately the authors could have gone further by simply rejecting
Subpart B altogether. Though this may initially seem reckless, 45 C.F.R.
§46.111(b) would provide adequate protections that could recognize the
uniqueness of the fetal-woman relationship. Section 46.111(b) lists five
subpopulations: "children, prisoners, pregnant women, mentally disabled
persons, or economically or educationally disadvantaged persons." 26 Two of
258. See Schonfeld, supra note 49, at 204.
259. See Junod, supra note 136, at 2.
260. See, e.g., Mary C. Blehar, Catherine Spong, Christine Grady, Sara F. Goldkind, Leyla
Sahin & Janine A. Clayton., Enrolling Pregnant Women: Issues in Clinical Research, 23
WOMEN'S HEALTH ISSUES e39, e42 (2013); The Second Wave, supra note 3; Pregnancy and
Clinical Research, supra note 3; Reframing the Framework, supra note 3.
261. Blehar, Spong, Grady, Goldkind, Sahin & Clayton, supra note 260.
262. Id

263. Id at e41-42.
264. 45 C.F.R. § 46.111(b) (2013).
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them (the mentally disabled, and economically or educationally disadvantaged)
are not considered vulnerable enough to have a dedicated subpart. However, 45
C.F.R. § 46.111(b) requires IRBs to ensure that research involving the five listed
populations provide "additional safeguards . . . to protect the rights and welfare

of these subjects." 265 This protection would be provided even if a population
does not have its own subpart. For instance, the mentally incapacitated do not
have their own subpart, but IRBs are still aware of the complications of
conducting research in this population and alter their review accordingly. 26 6
Under this framework, Subpart B would be eliminated, but pregnant women
would remain in 45 C.F.R. § 46.111(b), which would provide them and their
fetuses with additional safeguards. This could help bring about the presumption
toward inclusion and force researchers to justify their reasons for excluding
pregnant women. 267 This is a vital, and long overdue change: "[s]ince the NIH
began to require inclusion of women, ethnic minorities, and children in research,
pregnant women are the only population for which justification for exclusion
does not need to be given." 268 Removing Subpart B and requiring IRBs to justify
exclusion would go a long way toward changing the feasibility of conducting
clinical trials in pregnant women.
Continuing to include pregnant women in the 45 C.F.R. § 46(b) regulations,
however, would indicate that the presence of a fetus does alter certain
considerations. But instead of allowing the IRB to automatically exclude the
pregnant population, the board would have to debate whether allowing pregnant
women in a particular research study was appropriate. IRB members could
continue to reference the previous Subpart B regulations as a consideration when
thinking of the ethical issues associated with pregnant women participating in
research, but they would no longer be bound to them in each individual research
protocol. For instance, IRBs might still require data in pregnant animals and
non-pregnant women before approving a protocol in pregnant women, however
the data demanded would need to be the least required to assure a minimum level
of safety. Furthermore, if in an individual case, an IRB did not think both sets of
data was necessary, it could only require one.
As the issue surrounding the IRB regulations has largely been one of
unnecessarily conservative IRB interpretation of the regulations, eliminating
Subpart B would need to be accompanied by IRB education. IRBs need to be
instructed about the importance of including pregnant women in research, and
why they need to grant approval when "additional safeguards have been
included." 269 This model acknowledges the importance of the fetus without
requiring that women's health, which directly impacts the health of their fetuses,
be jeopardized because of perceived fetal risk. This shift would also clarify that
265. Id.
266. GUIDEBOOK, supra note 19, at ch. 6 pt. D.
267. Blehar, Spong, Grady, Goldkind, Sahin & Clayton, supra note 260, at e41-42.
268. Id. at e42.

269. 45 C.F.R. § 46.111(b).
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"in practice the notion of maternal-fetal conflict poses a false dichotomy" and
that maternal and fetal health are in fact very hard to separate. 27 0
B. Create FinancialIncentives to Encouragethe GenerationofDrug-Safety
Data
Refraining the IRB regulations is vital to permitting pregnant women to
participate in clinical trials. Without incentives or requirements to produce this
research, however, drug companies are unlikely to spend the time and resources
to generate this information. There are a few possible methods to change this.
First, Congress could permit the FDA to require this data. This would be the
least expensive, and most effective way to generate this research given that the
cost would be incurred solely by the pharmaceutical industry. Unfortunately,
drug companies would likely vigorously oppose this regulatory shift due to its
great cost potential. Given the power of the pharmaceutical lobby, 271 such a
reform would likely be politically unfeasible. Second, Congress could set aside
funds exclusively for researchers studying the effects of drugs in pregnant
women. 272 This would require the government to find and set aside tax dollars to
support such a program, which given the current financial crisis and how
sequestration has effected NIH research grant funds, is also politically
problematic. 273 Finally, Congress could create incentives to produce this
information-for instance, through the creation of periods of regulatory
exclusivity, much like what was done in the pediatric context. 274 The argument
against this model is that it is expensive for drug consumers and creates a
windfall for the pharmaceutical industry. 275 This model, however, did produce a
wealth of information regarding drug safety in children and is generally
considered a success.
In the pediatric setting, after similar concerns about a lack of information,
Congress amended the Food and Drug Modernization Act in 1997.276 This law
provided a six-month period of market exclusivity for drugs that had undergone

270. Blehar, Spong, Grady, Goldkind, Sahin & Clayton, supra note 260, at e4l-42.
271. See Paul Blumenthal, Auction 2012: How Drug Companies Game Washington,
HUFFINGTON POST (Feb. 1, 2012, 12:56 PM), http://www.huffingtonpost.com/2012/02/01/auction2012-drug-companies-lobby_n_1245543.html ("There are few industries with as much power in
Washington as the pharmaceutical sector. Drug companies have spent $2.3 billion on lobbying and
$183 million on campaign contributions since 1998, according to the Center for Responsive

Politics.").
272. See Greenwood, supra note 3, at 315.
273. Fact Sheet: Impact of Sequestration on the National Institutes of Health, NATL. INSTS.
OF HEALTH (June 4, 2013), http://www.nih.gov/news/health/jun2013/nih-03.htm.
274. See Greenwood, supra note 3, at 310-11.
275. Id. at 314.
276. See Rebecca S. Eisenberg & John R. Thomas, Patentsand Regulatory Exclusivity in the
USA, in 2 ENCYCLOPEDIA OF HEALTH EcoNoMICs, 443, 447 (Anthony J. Culyer ed., 2014).
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pediatric clinical trials. 2 7 7 This exclusivity was tacked on to whatever exclusivity
the drug company already retained and did not require findings that the drug was
safe in children. 278 Regulatory exclusivity has similar benefits to the patent
system, but is protected through the FDA as opposed to patent infringement
litigation. If a drug company is entitled to this additional exclusivity, then the
FDA will not approve another drug to share the market space until that
additional six months has passed. 279 This has yielded a "significant increase in
available information about the effects of drugs in children." 280 Within a decade
of the law's enactment, over 300 pediatric studies had been conducted. 281
Moreover, "[w]hile there were only eleven pediatric labeling changes between
1990 and 1997, there were one hundred thirty between 1997 and 2007."282 The
cost of this information for drug consumers was significant, however, in that it
delayed the entry of cheaper generics by six months. 283 In the six months of
market exclusivity granted for pursuing research in children, drug companies
stood to make large returns on investment. 284
Kate Greenwood has examined whether this model would be appropriate in
the pregnancy setting. 285 She notes many criticisms of the pediatric exclusivity
provision, determining that "the host of concerns about the pediatric exclusivity
provision's cost and efficiency make it difficult to conclude that it should be
expanded to include pregnant women and fetuses." 286 Instead, she concludes that
a system of federally funded and mandated research would be ideal. 28 7 Even if
Greenwood's proposal would be better for consumers, her solution is financially
and politically impracticable in light of the current financial crisis and the
unwillingness of Congress to support efforts to conduct research on pregnant
women. 288
Legislation providing regulatory exclusivity for conducting clinical trials in
pregnant women-the most feasible option for generating important data in our
current political climate-should be pursued. If Congress was concerned about
277. Id.
278. Id
279. Id at 448.

&

280. Id.
281. See Jennifer S. Li, Eric L. Eisenstein, Henry G. Grabowski, Elizabeth D. Reid, Barry
Mangum, Kevin A. Schulman, John V. Goldsmith, M. Dianne Murphy, Robert M. Califf & Daniel
K. Benjamin, Jr., Economic Return of Clinical Trials Performed Under the PediatricExclusivity
Program,297 J. AM. MED. Ass'N 480, 480 (2007).
282. Greenwood, supra note 3, at 312.
283. Id. at 314.
284. Id. at 313-14.
285. Id at 314.
286. Id
287. Id. at 322.
288. See Li, Eisenstein, Grabowski, Reid, Mangum, Schulman, Goldsmith, Murphy, Califf
Benjamin, supra note 281.
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the potential cost to consumers, it could legislate a shorter period of exclusivity.
Additional months of exclusivity would create incentives for drug companies to
generate this research, as they would stand to make tens of millions of dollars.2 89
It is additionally important to note that while consumers may be financially
burdened by this system, they also stand to benefit from it. Without this
information, pregnant women will continue to be under-informed about the risks
of drug use and suffer health complications as a result. 29 0 Six months of delayed

generic entry may be a fair price to pay for such information, especially if it is
the only practical option available at this time.
C. Amend the Labeling Regulations Again to Display NeutralInformation on
Maternaland FetalRisks
Finally, once more data has been generated, the FDA should further alter its
pregnancy labeling regulations. With risk data in pregnant women available, the
new FDA labeling regulations represent an important step forward. However,
once pregnancy risk data is produced, altering the standards for pregnancy
labeling to reflect the standards for pediatric labeling will be the crucial, final
step. Pediatric labeling is minimal. 291 It requires a "pediatric use" section when
pediatric dosing differs from adult dosing; a description of human pediatric data
if such data indicates safety or risks; a neutral statement that pediatric studies
have not been conducted, if applicable, without drawing any conclusions one
way or another; and an indication of pediatric risks in either the "warnings and
precautions" or "contraindication" section. 292 Most importantly, animal data
should be used minimally-only when reliable human data is unavailable and
where the animal data is particularly predictive. 293 Appropriate disclaimers about
reliability should accompany animal data.
Displaying pregnancy data in this way would be more consistent with FDA
practice. The FDA's role is to require neutral information to be displayed on
drug labeling so that people can make autonomous, well-informed decisions on
drug consumption. Pregnant women are equally capable of evaluating risks and
determining what is in their best interests. The FDA must simply present data,
not attempt to bias decision-making one way or another. The only way to ensure
this occurs is to treat the risks of medication in pregnant women consistently
with other subpopulations.

289. If the median profit generation from six months of market exclusivity is $140 million
and the median cost of clinical trials is $10 million, then the median three month market
exclusivity should still yield around $60 million. See Greenwood, supra note 3, at 314.
290. See Part L.B.

291. See 21 C.F.R. § 201.57(c)(9)(iv) (2014).
292. Id.
293. For instance, when "drugs are tested in animals at doses which exceed the therapeutic
dose in humans, and certain animal species have different baseline rates of birth defects," there are
reasons to doubt the predictability of the data in humans. See Greenwood, supra note 3, at 284.

Imaged with Permission of N.Y.U. Review of Law & Social Change

88

N.Y U. RE VIEW OFLAW & SOCIAL CHANGE

Vol. 39:45

Taken together, regulatory reform of IRB regulations, market incentives for
generating data, and an amendment of FDA labeling requirements would greatly
improve access to, and proper display of, information regarding maternal and
fetal risk of drug consumption during pregnancy. Removing pregnant women
from the category of vulnerable populations would reduce the burden of
conducting research in pregnant women. Creating incentives for generating
human data through market exclusivity would remove any financial barriers and
encourage this data production. Finally, displaying this human data in a neutral
manner, without relying on animal studies, would make pregnancy information
more consistent with other risk subsections. These three changes would have a
huge impact on pregnant women. It would improve decision-making and greatly
reduce the risks inherent in drug consumption or drug avoidance.
CONCLUSION

Regulations that govern FDA labeling create an environment in which
pregnant women are discouraged from taking needed medications due to
potential risks to their fetuses. These precautions are based on a lack of human
data. This data is missing, however, largely because of overly protective and
paternalistic regulations that create a presumption against including pregnant
women in medical research. The bioethics community has harshly criticized
these regulations as paternalistic and dangerous to pregnant women. The best
way to solve this problem is to generate human data and display neutral
information in product labeling. This article has suggested three changes: (1)
removing pregnant women from the classification as a vulnerable research
population; (2) creating a system of market exclusivity to generate drug studies
involving pregnant women; and (3) altering FDA labeling regulations to
exclusively reflect this evidence. All three recommendations in tandem would
greatly improve pregnant women's access to reliable information on drug risks
and help them to make well-informed medical decisions.
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